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ABSTRACT 
In the mid 1990's the UK government began to focus on problem heroin use mainly 
as a drug related crime issue, and so attracting and retaining clients became a 
treatment priority. The concept of flexible prescribing, matching individual clients to 
treatment programmes appropriate to their drug using history and circumstances, 
began to gain support amongst politicians and clinicians. As part of this shift in 
emphasis, prescribing heroin to heroin addicts re emerged as a treatment option. 
Injectable (and smokable) diamorphine (pharmaceutical heroin) began to be 
prescribed in a small number of drug dependency units under the direction of local 
psychiatrists, including two in North West England. 
One hundred and thirty three registered drug users were interviewed between August 
1995 and February 1997 using a structured questionnaire. Three key areas and their 
association with heroin substitution prescribing were addressed; levels of criminal 
activity, levels of illicit drug use, and a range of client held perceptions and 
attributions regarding coping/quality of life. 
The mean age of the sample was 30 years, and 75% were male. 61% had used illicit 
heroin in the past month, spending on average £638, on a habit of 4g per week. 
Clients were subdivided on a number of variables and comparisons were made 
between groups according to (IV) prescription type (which drug), and form 
(injectable/smokable/oral mixture). Significant differences were found across each of 
three key variables, including differing levels of illicit drug use according to 
prescription form, and differing levels of specific criminal activity according to 
prescription type. Significant effects included; Clients on prescriptions which 
included ampoules were significantly more likely to report being able to cope with 
life, and spent significantly less time on drug taking activities, than those clients 
receiving other prescriptions. Clients on prescriptions which included `reefers' 
(smokable) reported significantly less shop lifting than clients receiving other 
prescriptions. 
It was concluded that the available empirical evidence regarding heroin prescribing is 
limited, and although some clinicians are yet to be convinced, it seems heroin does 
have its merits as a viable treatment option. Issues of cost and possible dispersion 
remain, and are discussed in relation to the continuing development of substitution 
treatment policy in the UK. 
Heroin and methadone substitution treatments; Harm reduction and 
the effectiveness of `flexible' prescribing for the treatment of opioid 
dependency. 
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Chapter One -- REVIEW OF THE LITERATURE 
Chapter One - REVIEW OF THE LITERATURE 
1.1. Heroin and heroin use 
1.1.1 Heroin 
"Among the remedies which it has pleased Almighty God to give to man to 
relieve his sufferings, none is so universal and so efficacious as opium" 
Thomas Sydenham (1624-1689) 
Known as either "the Shakespeare of medicine" or "the English Hippocrates", 
Thomas Sydenham was the founder and first president of the Royal College of 
Physicians. Sydenham was physician to the King and widely recognized as a founder 
of clinical medicine and epidemiology, he was also one of opium's' earliest 
supporters. (Encyclopaedia Britannica 2005) 
Heroin (derived from `heroisch' the German word for hero) was first synthesized in 
1874 from morphine, the main psychoactive ingredient of opium (others include 
codine). Morphine is reacted with vinegar (diacetic acid) producing diamorphine, or 
heroin, which has similar pharmacological properties but greater potency. (Gossop et 
al 2005) Opium is a naturally occurring substance extracted from the seedpod of 
certain varieties of poppy plants. It was first commercially marketed in 1898 as a new 
pain remedy, and became widely used in medicine in the early 1900s until it became a 
controlled substance following the 1917 Defence of the Realm Act. (It was observed 
that soldiers fighting through the first world war had begun to use heroin and 
politicians believed that this use could threaten its successful outcome). 
When injected, heroin produces a feeling of intense euphoria and pleasure, often 
followed by happiness and relaxation. Standard doses do not generally impair 
intellectual or motor ability (after the first 45-60 minutes), although larger doses can 
lead to light sleep or sedation. Smoking and sniffing heroin provides a milder `rush', 
whilst orally, heroin provides no `rush', hence its unpopularity as a method of 
consumption. 
1.1.2 Heroin use: prevalence 
Estimates of the prevalence of heroin are known to be imprecise for a number of 
reasons including sampling and reporting problems, and clients' reluctance to admit to 
using `taboo' drugs associated with more social unacceptability. According to the 
Drug Misuse Database, which monitored numbers of new problem drug users known 
to services in Britain from 1993 to 2001, in the six months ending September 1993, 
7,700 `new' clients (either presenting for the first time or following a minimum six 
month break from treatment) reported that heroin was their main drug of use. In the 
six months ending March 2001; this number had risen to 22,431. (Dept of Health, 
2002a) According to the Home Office, the number of notified heroin addicts increased 
from 14,447 in 1995, to 30,573 in 1996 (Home Office, 1995,1996) 
(see Table 1.1 below) (the Addicts Index, which focused on opiate and cocaine 
addicts known to doctors, was ended in 1996) 
Table 1.1: Numbers of drug offenders and notified drug addicts in Britain, 1975- 
2000 
Drug offenders - Notified drug addicts 
Cannabis Heroin Cocaine Amphet. LSD Ecstasy TOTAL Heroin TOTAL 
1975 8987 393 379 1501 826 - 11846 812 1458 
1980 14912 751 476 827 246 - 17158 1657 2441 
1985 21337 3227 632 2946 539 - 26958 8090 8819 
1990 42209 1605 860 2330 915 286 44922 14497 17755 
1995 76694 4219 2073 10364 1268 3281 93631 24530* 37164* 
2000 75985 12297 5451 6637 260 6630 104390 
notes: 
* There were 30,573 heroin and 43,372 in total addicts in 1996 (last year of Notified Addicts 
Index) 
Sources: Home Office (1997). Statistics of drug addicts notified to the Home Office, UK 1996. 
London: Home Office 
Home Office (2002). Drug seizure and offender statistics, UK, 2000. London: Home Office 
The figures above illustrate the rapid rise in the number of heroin offenders in relation 
to other drug users; from only 393 in 1975 when heroin offenders were amongst the 
lowest number, to 12,297 in 2000, second only to cannabis. 
In order to try and improve the accuracy of the figures, researchers have estimated the 
total prevalence of opioid clients from the number of notified opioid clients, by 
employing a multiplier of five (see Hartnoll et al., 1985, for the London-based study 
which originally suggested this multiplier). Applying this multiplier to the final count 
of notified drug addicts in Britain in 1996 (43,372) produced an estimated total 
prevalence of about 216,000 drug addicts - including about 200,000 addicts of heroin 
and/or methadone. (Frischer et al. 2001). Estimates for the UK in 1998 put the total 
number of heroin users at 299,000 (about 1% of the adult population) (Bramley- 
Harker 2001). 
In the case of heroin, prevalence may now (2005) be as high as 300,000, compared 
with about 200,000 in the mid-1990's, 50,000 in the mid-1980's, 10,000 in the mid- 
1970's, less than 5,000 in the mid-1960's and less than 1,000 in the mid-50's. 
(Newcombe 2006, in press). 
1.1.3 Heroin use: consumption 
Patterns of heroin consumption have changed considerably over the last 80 years, in 
terms of users, drug, and form. In the first half of the 20th century it was used mainly 
by medics and iatrogenic addicts, and by soldiers in the First World War. Heroin 
developed through the `hippys' of the 1960's in the South East, into a drug associated 
with poor/unemployed working class addicts around the country from the 1980's. 
Between 1960 and 1980 street heroin was most often injected or sniffed, and came in 
the form of a pure white crystalline powder, known as `Chinese White'. The 1980's 
saw the arrival of a cheaper alternative, originating in Pakistan and Afghanistan, a 
brown and often heavily adulterated product which could also be smoked -a factor 
which increased its appeal to a wider audience. Dealers would `cut' the heroin with a 
variety of adulterants (to maximise profits) including lactose, glucose, chalk, 
paracetamol and caffeine (for example, caffeine is added because it increases the 
`smokability' of brown heroin). The levels of purity, and in particular the presence of 
potentially harmful substances in unknown quantities, is a factor in the argument for 
the controlled prescription of pure unadulterated heroin to reduce the risk of 
accidental overdose and to address other health issues. The purity of heroin over the 
last 20 years is shown in Table 1.2. (The purity of `street' deals is about half the 
official rate, ie. 15-25%) 
In Britain today, users' slang names for heroin include `gear', `smack', `skag', and 
`brown'. Injecting heroin is called shooting up, cranking, digging and fixing - while 
smoking heroin is called `chasing' or `tooting' 
Table 1.2: Purity of illicit powder drugs in England & Wales; Police seizures, 
1984-2003 
HEROIN 
1984 43-48% 
1985 36-43% 
1986 30-38% 
1987 29-32% 
1988 33-41% 
1989 35-40% 
1990 36-40% 
1991 37-47% 
1992 41-47% 
1993 29-48% 
1994 39-44% 
1995 40-44% 
1996 44-45% 
1997 35-36% 
1998 34-41% 
1999 39-46% 
2000 41-51% 
2001 43-54% 
2002 34-45% 
2003 28-42% 
Source: Mwenda L. et al (2005). Drug seizures in England & Wales 2003. London: Home 
Office 
(Figures from 1992 based on seizures in E& \V only (prior to 1992, figures are for UK) 
figures are ranges for quarterly purity statistics) 
Estimates of the average prices of standard retail units (a gram/dose/ounce) and 
wholesale amounts (kilograms/thousand doses) of drugs are compiled by the National 
Criminal Intelligence Service (NCIS) from figures provided by local police forces and 
other experts. National averages are shown in Table 1.3 below. Prices in many cities 
and towns fluctuate from the national average depending on supply and demand. For 
LIVcr OJL 
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instance, the cheapest heroin can now be purchased in Liverpool and Manchester, 
where a gram costs around £25-£30 in 2005. (anecdotal) 
Table 1.3: Retail price (£) of illicit drugs, UK, 1997-2000 
Cannabis 
Skunk Resin Herbal Heroin Cocaine 
1997 163 97 95 74 71 
1998 154 93 91 74 77 
1999 151 100 89 65 63 
2000 145 85 82 70 65 
Retail units: grains for heroin, cocaine; ounces for cannabis; 
Source: Home Office (2002). Drug seizure and offender statistics. London: Home 
Office. 
1.2 The British System; Key changes/influences in the approach to substitution 
treatment provision in the UK. 
It continues to be the case that opioid dependency is an increasing issue in the United 
Kingdom, with high individual, communal and societal costs. Heroin dependence is 
perceived by clients, practitioners, researchers, policy makers and law enforcers alike 
to present major health problems and costs to the individual and to the state. In 2001- 
2002 the Audit Commission (2002) estimated that the treasury, on drug related 
problems, spent between three and four billion pounds. Clearly the issue of heroin 
dependence has high medical, legal, individual, social and criminal costs, and the 
debate concerning the impact of prescribing heroin and methadone substitution 
treatments on these respective costs continues to be played out by researchers and 
policy makers alike. In the often highly charged atmosphere of public health, the 
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notion of flexible prescribing, tailoring treatment options to the needs of the 
individual rather than the policy of the service, continues to be a controversial one. 
1.2.1 Substitution treatment 1920's -1960's 
The last 80 years have seen the UK response to opioid dependency vary enormously, 
reflecting changing perceptions regarding the notion of addiction, different political 
and historical contexts, and power shifts between the legal and medical professions. 
The option to discuss and implement the prescribing of heroin and other opiate drugs 
seemed far from the minds of those pushing for the prohibition of opium, heroin, 
morphine and cocaine in 1920's Britain. (Dangerous Drugs Act). However it soon 
became clear that rather than purely criminalise heroin dependency, as in the USA, 
British policy makers and health care providers believed that there was a significant 
medical aspect to the issue which should be recognised in service delivery and 
treatment options. 
The UK remains distinct in the fact that it is one of the few countries, which 
incorporates the prescription of pharmaceutical heroin (diamorphine) in the range of 
treatment options available to those dependant on opiates. In 1926 the government 
accepted the advice of the Rolleston Committee (Departmental Committee on 
Morphine and Heroin Addiction, 1926) who published a report establishing the right 
of medical practitioners to prescribe opiates for the treatment of certain patients, and 
from this report `the British System' was born. 
"Prescribing opium for addicts is reasonable if the patient could not be 
withdrawn without serious withdrmval symptoms; if the patient was 
undergoing a gradual withdrmval; and if the patient needed the drug to lead a 
useful and normal life" Rolleston Committee 1926 
The treatment for opioid dependency was now (1920's - 1960's) seen as the domain 
of the medical practitioner, and if that practitioner felt that with a prescription for an 
opioid drug the patient would be more able to lead a "useful and fairly normal life", 
not otherwise possible, then the prescription protocol was met and the drug/s were 
prescribed. As the quote above detailed, this protocol Evas broadly divided into three 
categories; those who could not lead a `normal' life unless a certain minimum dose of 
an opioid drug was administered; those who would experience unsafe and significant 
withdrawal symptoms should the opioids be discontinued; and those requesting a 
managed supervised withdrawal scheme. 
Strang (1989) highlighted the fact that one of the main features of `the British System' 
was its distinct lack of any central system, as in practice, the vast majority of 
prescribing doctors were community based general practitioners. These practitioners 
were essentially autonomous individuals charged with the development of treatment 
prescribing programs in accordance with their own professional experience and 
perceptions of the client needs. Stimson and Metrebian (2003) concluded that on the 
whole this approach worked well with those clients presenting at the time, most of 
whom were `middle class' professionals having become dependant through the 
prescription of opiates for medical treatment ("known as therapeutic or iatrogenic 
addicts"), or directly because of their exposure to opiates as a result of their position 
in the medical/nursing profession. The main feature of `the British system' continued 
to be maintenance and management of the addiction in a medically controlled manner 
delivered by general practitioners. 
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Historical commentators would be keen to point out to future policy makers that this 
system was born at a time when the extent of the opiate dependency issue was 
minimal in the UK. Praise has been offered to the `British System' with the fact that 
there were relatively few dependent users being offered as a indicator of its success. 
However, others (eg. Strang 1989) believed that the system, (operating at a time when 
few individuals were dependent on morphine and even fewer on heroin) only worked 
because there were so few dependent users. 
In the 1960's the `British System' began to be challenged because heroin dependence 
in young people began to be seen as a significant issue. A very different group of 
clients was formed who initially obtained their drugs from private general 
practitioners, mainly in London. It was becoming increasingly clear that a `black 
market' was being created, made possible by a small number of private practitioners 
over prescribing (Spear 1994). It was suspected that the `system' was actually 
encouraging the rise of the problem, making supplies readily available to those who 
could afford them, and drug dependency was seen as a socially transferable `illness' 
which required treatment. As a direct result of the increasing level of concern 
regarding the rise of a potential black market, the Brain Committee was first convened 
in 1961 (Interdepartmental Committee on Drug Addiction, 1961). Although this initial 
committee concluded that the overall problem was still relatively too small to warrant 
large scale changes to the policies and practices already in place, it was soon to 
reconvene in the light of a global increase in recreational drug use and hedonism as 
the 1960's got into full swing. Stimson and Metrebian (2003) concluded that those 
doctors who thought they were helping to contain and prevent any illicit heroin 
I0 
market were in fact fuelling it, by over prescribing to individuals who would then sell 
part of their `script' to those seeking (initially) to use heroin for recreational pleasure. 
The early 1960's saw another key development with the resurgence in the use and 
popularity of methadone, a synthetic opiate drug originally invented by the Nazi's 
during World War Two. According to popular legend in Germany, methadone, 
invented as a substitute for heroin, was initially christened Dolophine in honour of 
Adolf Hitler. In reality, the name comes from the Latin dolor, meaning, "pain", and 
fin, meaning, "end": hence "end of pain". The Allies had managed to stop supplies of 
heroin reaching the German troops, without effective pain relief the German war 
effort would soon be over. German scientists were charged with inventing a 
replacement, and methadone was created. Following the defeat of the Germans, 
methadone became a largely forgotten drug until 1965 when it was `rediscovered' by 
two American doctors, Dole and Nyswander who hailed it as an ideal maintenance 
treatment option for those individuals presenting with an addiction to heroin, and 
`substitute prescribing' was born.. (Dole and Nyswander 1965). They highlighted two 
key advantages methadone held over heroin; the first that it was dispensed in syrup 
form and therefore able to be administered orally (and not amenable to injecting), and 
secondly, that it was long lasting (up to 30 hours as compared to up to eight for 
heroin) and clients could therefore be given single daily doses. A third advantage was 
that it was far less `pleasureable' than heroin, though it did stop withdrawals. When it 
did reconvene, the Brain Committee encouraged practitioners to consider methadone, 
not just as a form of maintenance, but also increasingly as a drug of withdrawal. 
11 
The second Brain report in 1965 also recommended the development of a compulsory 
notification system for drug clients, the establishment of specialist drug dependency 
clinics, and maybe most significantly the restriction of heroin prescription to clients to 
a smaller number of licensed doctors - generally psychiatrists. (Interdepartmental 
Committee on Drug Addiction, 1965). Drug treatment began moving from GPs to 
specialist multi-disciplinary drug clinics, and from maintenance on various drugs to 
maintenance on methadone only - and later toward methadone detoxification only. 
The Brain report directly resulted in several significant developments leading to the 
demise of `the British system' and changes in legislation, most notably the Dangerous 
Drugs Act of 1967, and the establishment of Drug Dependency clinics in 1968. 
Following the Dangerous Drugs Act (1967) Home Office approval, by way of a 
specific license, had to be gained by any doctor wishing to prescribe either heroin or 
cocaine to clients. The establishment of the Drug Dependency clinics represented an 
important shift in emphasis relating to the response of healthcare professionals. In 
their first year of operation [mostly in London], Strang (1989) reports that 1,306 
clients were registered at the clinics, mostly dependent on heroin. The emphasis was 
now one of dual aims; to treat the addict with appropriate medical intervention, and to 
treat the `problem' in terms of the spread/social costs of increased heroin availability. 
"The tension between treatment and care on the one hand and social control on the 
other has since been a continuing feature of drug policy and medicine's involvement 
in this field" (Stimson and Metrebian 2003, p6) 
1.2.2 Substitution treatment 1970's -1980's 
In the early 1970's drug dependency units began moving away from prescribing 
heroin, favouring oral (and sometimes injectable) methadone. In effect, drug 
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dependency units were pushing for detoxification and withdrawal regimes, with 
abstinence rather than maintenance, being the treatment goal. This was echoed in the 
law enforcement arena, with the introduction of the 1971 Misuse of Drugs Act, which 
extended prohibition to many more drugs and increased associated penalties. In short, 
drug services were now there for one purpose: to help people `get off drugs, as the 
sole alternative to being criminalized for them. This new abstinence-only policy lasted 
for almost two decades. Those who favoured this change in treatment cited two major 
issues; a generally improving regard for the use and effectiveness of methadone, and 
the continuing concerns about `black market' leakage of prescribed heroin. Ashton 
(1981) supported this latter belief, concluding that maintenance prescribing was not 
stabilising many users, and that there was evidence of continued criminal activity and 
`topping-up' prescriptions with illicit heroin. 
It is certainly true to say that some argue this shift in emphasis was neither prompted 
nor widely supported by research findings. Fazey (1989) stated that the changes in 
policy, far from being based on sound empirical findings, were in fact the result of a 
small but influential group of (mainly) psychiatrists who adopted the moral high 
ground and declared that drug users should not be prescribed drugs of their own 
choice. In a sense this represented a medical/professional `fashion'; imposed upon 
those who were expected to follow. Fazey (1989) pointed out "There is no tradition, 
in the UK at least, of evaluation of treatments. Research has always been done on the 
effects of particular drugs and their effectiveness in bringing about physical changes 
and controlling disease, but not evaluations which look at other variables". 
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(It should be noted that from the early 1990's there was a sharp increase in the amount 
of research in most areas of the drugs field, and the conclusions of some of the 
treatment focused work will be discussed in later chapters). 
Those who had not favoured this change in focus argued that by the mid 1970's there 
was a growing level of disillusionment with this shift in emphasis and its resulting 
treatment `options' with medically administered heroin maintenance programs 
replaced by methadone treatment/reduction programmes, administered through Drug 
Dependency Units. (Marks 1990) 
There was no formal change in policy to support the move away from prescribing 
heroin, and the findings of the first (and to date, only) randomised control trial 
comparing oral methadone to injectable diamorphine, proved inconclusive. (Hartnoll 
et al 1980). This study is presented in more detail in section 1.4.1, however it seems 
fair to suggest that those who elected to use Hartnoll et als' findings to justify a 
change in reverting back to methadone and away from heroin were doing so against 
the aims of the authors; 
"It (the Hartnoll and Mitcheson study) has been widely credited with 
changing treatment policies in the newly established Drug Dependency Units 
away from heroin maintenance to policies focused on short-term methadone 
prescribing, and towards abstinence as a goal. It formed the basis of 
guidelines on good clinical practice issued in 1984. This was certainly not the 
aim of the researchers. Despite the author's reservations about the results, the 
research was taken to show that oral methadone maintenance treatment was 
preferable. " (Berridge & Thom 1996, p25) 
In 1982 the ACMD produced its report `Treatment and Rehabilitation' which resulted 
in many of the mainly methadone detoxification centred Drug Dependency Units 
14 
being gradually transformed into Community Drugs Teams. The multi-disciplinary 
CDT's involved a wide range of professionals including social workers, probation 
officers and youth workers, alongside the traditional nurses and psychiatrists. In 
essence the policy of harm reduction was beginning to emerge (mainly from 1988), 
and detoxification/abstinence, whilst still on the agenda, were placed firmly behind 
attracting clients and maintenance in terms of treatment emphasis. 
In a landmark article in The Lancet, a prominent psychiatrist and supporter of the 
prescription of heroin to clients, Dr John Marks, set out his views on the debate 
surrounding such a treatment option. (Marks 1985) They have remained central to the 
ongoing and controversial area of prescribing heroin to heroin addicts, and are 
summarised in the table below; 
Table 1.4: The arguments concerning the prescription of heroin. 
Against For 
1. It maintains the condition of addiction; The addict will remain in the condition 
anyway; 
2. It was a public health exercise to A stable supply benefits the addict and 
protect people from the black market; provides pure, clean drugs; 
3. It is not a doctors job to control the Doctors are obliged, like anyone else, to 
illicit use of drugs; help society combat the breaking of the 
law; 
4. Barbiturates and alcohol are not If alcohol were prohibited, it would be 
prescribed because they are damaging - more humane to prescribe a daily dram of 
why opium? whisky than to see someone sell their last 
possessions for methelated spirits; 
5. The illegal use of drugs is not curbed There are still insufficient properly 
by prescriptions; controlled clinics; 
6. Addicts traffic their prescriptions; Prescribe less; 
7. Addicts supplement their prescriptions Prescribe more; 
8. The efficacy of maintenance is not The contrast between the USA and 
proven; England between 1920-1960 suggests 
otherwise. 
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Both sides of the argument have been developed over the past twenty years and now 
include the following three areas of debate in addition to Marks (1985) initial 
thoughts; 
Treatment. In terms of treatment those against prescribing heroin fear that this may 
dissuade clients from even considering alternatives such as methadone, and encourage 
them to maintain their addiction longer by making it easier for them to inject their 
(now free) drug of choice. They also argue that the cost of maintaining large numbers 
of clients on relatively expensive (as compared to methadone) prescriptions will 
restrict the number of clients who could be treated, given the fact that any treatment 
service has finite resources. Those in favour of prescribing argue that offering heroin 
as a treatment option would attract more clients, and would see them remain in 
treatment longer, receiving a range of health related and social/educational 
interventions, thus reducing demands on other areas such as hospital admissions and 
law enforcement agencies. (Gossop 2000) 
HIV/AIDS. Those against prescribing argue that increasing the regularity, with which 
clients inject, even if they are injecting prescription drugs, still increases the 
likelihood that they may suffer adverse consequences, including the transmission of 
HIV and other infectious diseases (eg HBV, HCV). Those in favour argue that the 
education and advice on injecting techniques and safe practice received by those 
clients on injectable scripts will in fact reduce the risks associated with injecting. 
They also argue that levels of purity can be assured by prescribing, and that once 
attracted and stabilised, clients may be more inclined/empowered to move away from 
injecting and onto oral methods. 
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Crime. This involves two areas of crime: acquisitive and drug dealing. First, those in 
favour of prescribing heroin argue that drug related acquisitive crime would reduce 
significantly, with the associated positive effects on the criminal justice system from 
police on the streets right through to the prison service. (Marks 1985) Clearly clients 
would not have to rely on acquisitive crime to support their drug habit, and this may 
in tern lead to improved job prospects and family stability. Those against focus their 
arguments on two key issues; firstly, the potential for leakage/diversion of surplus 
(high quality) drugs onto the streets, creating new users; and secondly, the relatively 
small amount of scientific evidence to support the prescribing of heroin (see 1.4.1) as 
compared to the wealth of evidence surrounding the effectiveness of methadone. 
Second, Marks (1985) also argued that heroin prescribing would reduce pyramid 
selling, including street level dealing, and this would reduce the prevalence of heroin 
use by making heroin harder to obtain. 
1.2.3 Substitution treatment; the impact of HIV/AIDS 
The Advisory Council on the Misuse of Drugs reviewed the evidence in `AIDS and 
Drug Misuse' (1988), which advised the government to prioritise a HIV prevention 
policy based on risk/harm reduction. The government accepted most of the advice in 
the report, leading to the setting up of a national network of new and revamped 
services - notably needle exchange schemes and more flexible methadone prescribing 
services (though Scotland was slower to respond). The government's official response 
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to the ACMD report again clearly indicated that harm reduction was to be prioritised 
over abstinence. It was now a public health priority to attract heroin users into 
treatment and to keep them in treatment long enough to positively impact on a'range 
of risk behaviours. This policy continued until 1994, when the government announced 
that abstinence was now the primary goal of drug services, with harm reduction 
becoming a secondary aim. (Task Force 1994) 
1.2.3.1 Flexible prescribing 
Flexible prescribing refers to the philosophy and practice of offering a range of 
treatment options, services and types of prescription, dependant on the individual 
nature of each client who presents to a service. 
In the context of illicit drug use and harm reduction, the option of flexible prescribing 
was given new impetus in the late 1980's and early 1990's by the rising threat of HIV. 
In 1988 the Advisory Council on the Misuse of Drugs (ACMD), (established by the 
Government), highlighted a need to increase awareness of the problems associated 
with HIV infection, particularly among injecting drug users. The ACMD had firmly 
moved the focus of service provision for drug users away from abstinence and toward 
inclusion to treatment and the reduction of HIV related risk behaviour: 
"The spread of HIV is a greater threat to public health than 
drug misuse. Accordingly, we believe that services which 
aim to minimise HIV risk behaviour by all available means 
should take precedence in development plans" 
(ACMD, "AIDS and Drug Misuse Part 1", 1988 2.1) 
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Endorsing a much more flexible approach to drug service provision, the ACMD led 
the push to encourage service providers to make and maintain contact with those drug 
users (making up the vast majority) who had previously not been attracted by 
detoxification / abstention focused services. 
Flexible prescribing would (it was hoped) attract those drug users who wanted to 
continue to use drugs. Service staff would then be in a position to work with clients on 
a `behaviour-change' hierarchy of goals, ranging from the cessation of sharing 
injecting equipment, through a move from injectable to oral drug use, towards 
reduction and eventual abstinence. Recognition was made that, as with other 
behaviour-change focused interventions, information alone was not enough. In a 
review of the literature concerning HIV and AIDS prevention, Valdiserri (1989) 
concluded that: 
"programs for HIV prevention must not limit themselves 
to modalities that are purely informational because of the 
fallacy that healthy behaviours can be induced merely by 
informing individuals of the dangers of unhealthy behaviours" 
(Valdiserri, R. `Identifying the targets of AIDS prevention' 1989) 
The shift towards a harm reduction focused, flexible prescribing approach was 
accompanied by a growing suspicion that many of the strategies initially adopted to 
deal with drug use, in fact exacerbated the problem. Prohibition was seen by many to 
be failing. A new approach to service provision, operating across a wide variety of 
levels from condom and needle availability, to counselling and non judgmental 
medical treatment, was seen by many as the only way forward; the only way to 
realistically address the issues of harm reduction, HIV prevention, reduction of 
criminal and anti-social behaviour amongst drug users and the wider community. 
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Reported rates of HIV infection amongst intravenous drug users varied considerably 
between countries at the time of the ACMD's first report. Fifty eight percent of 
intravenous drug users in New York City were antibody positive, 68% in France, 11% 
in Spain, 76% in Italy, 60% in Scotland and 1.5% in England and Wales. (Terrence 
Higgins Trust 1988) 
1.2.3.2 Injecting behaviour 
Table 1.5 presents the bi-annual number of problem drug users who inject, presenting 
to services (regional drug misuse databases) in Britain between 1993-2001. It also 
focuses on the percentage of those who share injecting equipment. The percentage of 
those injecting users rose steadily throughout the 1990's (with the exception of Sept 
95 - Mar 96), as did the overall number of injecting drug users known to services. 
Table 1.5: Bi-annual number of PDUs, 1993-2001; and (a) percentage of PDUs 
who are injecting drug- users (IDUs); (b) percentage of IDUs sharing injecting 
equipment in past month (SIE) 
Six months ending: TOTAL Over all % % injecting drug users 
IDU SIE Heroin Amphets 
March 1993 20343 38 .. 61 51 Sept. 1993 20221 43 13 69 54 
March 1994 21582 42 12 68 54 
Sept. 1994 23707 41 12 65 51 
March 1995 25440 38 12 59 48 
Sept. 1995 27935 37 11 58 47 
March 1996 28856 36 11 54 45 
Sept. 1996 30292 37 12 52 43 
March 1997 31684 37 12 52 42 
Sept. 1997 27262 39 15 58 44 
March 1998 29765 38 15 58 45 
Sept. 1998 34875 39 17 57 47 
March 1999 34802 41 17 60 48 
Sept. 1999 37681 39 19 58 47 
March 2000 39055 40 20 59 41 
Sept. 2000 40416 40 21 58 38 
March 2001 40181 38 20 54 40 
Source: Department of Health (2002). Statistics from the Regional Drug Misuse Databases for six 
months ending March 2001. London: Government Statistical Service [and previous bi-annual 
bulletins] 
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1.2.4 Substitution treatment: the relation to crime 
The relationship between drug use/users and crime became the focus for prescribing 
policy and practice from the 1990's. The Government viewed drug misuse as an issue 
directly related to criminal activity, and instructed service providers to expand heroin 
(and other drug) treatment services to encourage as many clients into treatment as 
possible. (Gossop 2000) Those in favour of offering heroin on prescription saw this as 
an opportunity to attract into treatment, and away from crime, those clients previously 
deterred by the essentially methadone-only clinics; by offering a range of drugs, 
including injectable diamorphine. However, only about a dozen clinics prescribed 
heroin to more than one or two clients during the 1990's (Strang and Gossop 1994). 
The UK had seen a steady rise in drug related crime throughout the 1970's. The 
1980's and in particular the 1990's saw this rise increase significantly, with the 
number of heroin related drug offences doubling from 2151 offences in 1987, to 4219 
offences in 1995. (see Table 1.6) 
Table 1.6: Annual number of drug offences, by heroin and methadone - UK, 
1973-2002 
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HEROIN METHAD. ALL 
1973 435 347 14,977 
1974 444 464 12,532 
1975 393 484 11,846 
1976 464 416 12,754 
1977 393 347 12,907 
1978 483 369 13,604 
1979 520 299 14,339 
1980 751 363 17,158 
1981 808 445 17,921 
1982 966 404 20,356 
1983 1,508 379 23,442 
1984 2,446 411 25,240 
1985 3,227 413 26,958 
1986 2,259 280 23,905 
1987 2,151 191 26,278 
1988 1,856 162 30,515 
1989 1,769 172 38,415 
1990 1,605 154 44,922 
1991 1,466 145 47,616 
1992 1,415 191 48,927 
1993 2,164 10* 68,480 
1994 2,971 10* 85,691 
1995 4,219 30* 93,631 
1996 5,929 409 95,198 
1997 8,892 719 114,640 
1998 11,751 790 131,230 
1999 12,960 720 121,980 
2000 12,430 620 105,190 
2001 12,390 570 100,940 
2002 11,790 470 110,920 
Source: Home Office (2004). Drug Seizure and Offender Statistics, UK, 2001 & 2002 (& 
Supplementary Tables). London: Home Office [Issue 08/04] 
* methadone figures for 1993 to 1995 are for Scotland and N. Ireland only. 
The transparency of the link between drug use and crime has led to much discussion 
amongst UK practitioners, policy makers and politicians alike. In the early 1990's 
problem drug use, and in particular heroin use, was highlighted by the government as 
a major crime and public order issue. Introducing his governments white paper 
`Tackling Drugs to Build a better Britain' Tony Blair asserted his commitment to 
"break once and for all the vicious cycle of drugs and crime which wrecks lives and 
threatens communities" (Home Office 1998). 
The National Treatment Outcome Research Study (NTORS) was commissioned by 
the Department of Health in 1994 as a large scale follow up research project to 
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evaluate the effectiveness of various drug treatment strategies. Gossop et al (1998) 
reported high rates of criminal behaviour amongst the treatment sample, with 61 % 
reporting a total of nearly 80,000 crimes in the three month period prior to embarking 
on the treatment programme. The most common of these crimes were shoplifting, 
burglary and robbery, and clients averaged one crime each per day. (NTORS will be 
discussed further in 1.4.3) 
The government were keen to centre their policies on breaking the links between 
crime (acquisitive crime in particular) and drug users needing to meet the needs of 
their habits. The argument being that heroin prescriptions would attract clients into 
treatment, thereby reducing and/or eliminating their need to commit crime. Bennett 
(2000) carried out a Home Office study of 506 arrested drug offenders, 29% of whom 
tested positive for opiates, and found that heroin users spent on average £16,000 per 
year on their habit, 81% of which came from crime (£13,000) 
Links between drug use and crime still play a major part in drug treatment strategy, 
and will be further examined in the final chapter of this thesis. 
1.3 Recent developments in the treatment of opioid addicts 
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Recent developments in drug treatment policy include the following; 
Tackling Drugs to Build a Better Britain. In 1998 the Government published its 
White Paper' Tackling Drugs to Build a Better Britain 1998-2007, and updated this in 
2002 with a 2003-2008 strategy. (Home Office 1998,2002) The four key aims of the 
initial 10-year strategy were; 
" reducing the supply of illegal drugs 
" preventing young people from becoming drug misusers 
9 reducing drug-related crime 
" reducing the use of drugs through increased participation in treatment 
programmes. 
Under each aim were listed several objectives, and more importantly, targets. 
(Performance indicators with specified levels of change and amount of change) 
In the subsequent updated strategy, specific reference was made to increasing the 
availability of heroin on prescription; "all those with a clinical need for heroin 
prescribing will have access to it under medical provision safeguarding against the 
risk of seepage into the wider community" (Home Office 2002), In 2005 this 
materialised as an injectable heroin prescribing experiment at 3 DDU's in Britain. 
Subutex. Subutex is the trade name for buprenorphine, and is a synthetic opiate 
similar to methadone, though it is a partial opioid antagonist (ie. It blocks the effects 
of heroin) It was licensed in 2001 as an alternative drug to be used in detox or 
maintenance. 
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Withdrawal management drugs. These reduce residual withdrawal symptoms (eg. 
Britlofex, clonidine), or block the effects of heroin (antagonists, preventing relapse, eg 
naltrexone). 
National Treatment Agency for Substance Misuse (NTA). The NTA is a special 
health authority (as opposed to a regional health authority), which was established in 
2001 with national responsibility to improve the quality and availability of treatment 
for drug users in England. The NTA initially set out to do this through; 
41 monitoring growing annual expenditure, including £200 million on treatment 
services for 2002/03 
" providing guidance on the commissioning of treatment services to local 
DAT's (Drug Action Teams) & DAAT's (Drug & Alcohol Action Teams) 
0 improving the availability and skills of staff in the drug treatment sector 
0 ensuring that users are consulted in the development of services 
A major contribution by the NTA is `Models of Care' (2002), which has three key 
components: a four tier framework (including tier three which includes 
maintenance/detoxification programmes), care concepts (including Integrated Care 
Pathways ICP's, dynamic and flexible individual treatment plans), and monitoring 
(the delivery, cost and outcomes of services, locally and nationally). 
In January 2002, the NTA released a media statement confirming that they were to 
convene a consensus group of national and international academics and clinicians, to 
discuss the issue of prescribing heroin; 
"Heroin prescribing is already available to specially-licensed clinicians as one of a 
range of treatment options. It is not the answer to all heroin misusers' problems, but 
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we believe that it has a role to play within the whole range of treatment options. We 
want to examine if heroin prescribing may be appropriate for a wider range of users" 
Paul Hayes, Chief Executive, NTA (2002) 
National Drug Treatment Monitoring System (NDTMS). In 2001 the National 
Drug Treatment Data Base was established to replace the Drug Misuse Database, 
which had operated between 1993-2001. Among various changes, the key 
developments included extending the annual count of PDU's from new clients to all 
(new and continuing) clients. 
These developments will be discussed in relation to the findings of the present study 
in the concluding chapter. 
1.4 Evaluating the effectiveness of heroin/diamorphine substitution prescribing 
1.4.1 The evidence base 
Very few studies have specifically examined the effectiveness of prescribing heroin to 
heroin clients. In a landmark thematic review of the literature Ashton and Witton 
(2003) concluded that worldwide just five key studies hold the answer as to whether 
such a policy can work. Three of these studies were carried out in the UK. 
According to the Home Office Notified Addicts Index (discontinued in 1996), the 
number of people prescribed heroin in the treatment of drug addiction declined from 
437 in 1970 (31% of all notified addicts) to 119 in 1996 (less than 1% of all notified 
addicts). Though various British studies of opiate clients prescribed heroin have been 
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published, by 2002 there were only three studies specifically comparing the outcomes 
of heroin prescribing with those of methadone prescribing: Hartnoll et al. (1980), 
McCusker et al (1996) and Metrebian et al. (2001). 
A pioneering study of heroin prescribing, conducted between 1972 and 1976, 
involved heroin clients seeking a maintenance prescription of injectable heroin from 
the University College Hospital, London; they were randomly allocated to receive 
either injectable heroin or oral methadone. This study remains the only British 
randomised comparison of methadone and heroin prescribing. Participation in the 
study was restricted to those clients between the ages of 18 and 35, who had a 
minimum of 3 months history of daily injecting, who had no history of psychiatric 
illness, who lived in London, and for whom all alternative treatment interventions had 
failed. Nearly all participants had criminal convictions. 
Information was collected on 96% at the outset and at 12 months (whether still 
attending clinic or dropped out). Significantly, the drop out rate from oral methadone 
treatment was much greater (71 %) compared with the heroin group (26%) at 12 
months. The main findings are summarized in Table 1.7 below: 
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Table 1.7: Summary of Outcome differences between IH and OM clients after 12 
months (Hartnoll et al 1980) 
AT 12 MONTHS: Injectable heroin 
Using <5mg heroin daily 10% 
Injecting regularly 90% 
Attending regularly 76% 
Convicted of crime in past year 50% 
Oral methadone 
32% 
57% 
29% 
70% 
Use of non-opiates in past year no difference 
Employment 44 
Health " 
Mortality rate " 
IN LAST 3 MONTHS: 
Did not inject for 31+ days 5% 30% 
It is clear that a year after starting treatment, those prescribed injectable heroin were 
more likely than those prescribed oral methadone to report injecting and heroin use - 
as expected given their prescription. However, overall the main differences after one 
year in treatment were that, compared with those prescribed oral methadone, those 
prescribed injectable heroin (1) were over twice as likely to have remained in contact 
and (2) were less likely to have been convicted of crime - with no differences between 
the two groups in other drug use, employment, health or mortality. (see table 1.7) 
In several key areas there were small but not statistically significant differences 
between the 2 groups; at 12 months 36% of participants on injectable heroin had 
reduced illicit opiate use to twice a week or less, as compared with 41% of those on 
oral methadone. Focusing on the remaining users in each group, 26% of those in the 
injectable heroin group reported continued `heavy' use, as compared to 37% of those 
on oral methadone 
It was in the area of crime and crime related activity that the two groups differed the 
most. At 12 months 61% of the oral methadone group reported that criminal activity 
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remained a major source of their income, compared with 43% of those in the 
injectable heroin group. 50% of the injectable heroin group had avoided arrest, and 
81 % had avoided prison, as compared with the oral methadone group who reported 
figures of 28% and 68% respectively. Ashton and Witton (2003) point out that in 
relative terms the injectable heroin doses were much less generous than the oral 
methadone doses, and as a result may have contributed adversely to levels of crime 
and drug use reported by the injectable group. 
Hartnoll et al (1980) concluded that the results did not indicate a clear overall 
superiority of either approach, and that relative advantages/disadvantages could only 
be considered according to the priorities assigned to the various outcomes, e. g. health 
compared with criminal activity. It is also of note that the ethical implications of 
randomly allocating clients to treatment conditions may in part explain why this study 
remains the only one of its kind in the UK to date. 
McCusker at al (1996) reported the findings of a 1995 community drug team study, 
looking at 66 long term clients (averaging 10-12 years of opiate use) attending one of 
three clinics run by the same team in Greater Manchester. Two clinics offered oral 
methadone maintenance only, whilst the third also offered injectable diamorphine. 
The 39 oral methadone group members were broadly matched (for age, gender, length 
of opiate use) with 27 clients in the injectable diamorphine group. When interviewed, 
again after approximately 12 months, 69% of the methadone group were using illicit 
heroin, as compared to 22% of the diamorphine group. Those in the diamorphine 
group also spent less money on illicit drugs, and less time engaging in criminal 
activity; reporting committing non-drug crimes on two days in the last 30, as 
compared to an average of six days reported by the methadone group. 
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In contrast to the relatively low doses of diamorphine prescribed in study reported by 
Hartnoll et at (1980), the dosing in the community team study was much more 
flexible, averaging 253mg for the diamorphine group and 72mg for the methadone 
group. (McCusker et al 1996) However, there was no pre treatment data, and data 
from those who dropped out of treatment was not collected, making it difficult to 
conclude with any degree of certainty the relative effects of prescription group over 
and above a whole range of other factors including the personality of the individual, 
personal circumstances etc., as well as pre-treatment behaviour patterns. 
The third and most recent British study looking at substitution prescribing, reported 
by Metrebian et al (2001) focused on 58 long-term treatment-resistant opiate clients 
starting treatment at a London drug clinic between mid-1995 and the end of 1997. 
To be eligible to take part clients had to be regularly injecting, they had to have 
experienced various drug-related problems despite receiving relatively high doses of 
prescribed oral methadone. Clients were asked to choose a prescription of either 
injectable heroin or injectable methadone - 37 chose heroin and 21 chose methadone. 
Of the 36% who chose methadone, most did so because it was their primary drug of 
addiction, and/or they preferred the longer duration of action. Drugs were dispensed 
on site, with weekend take-home prescriptions, with a maximum daily dose of 200mg 
for either drug (which again, as with the Hartnoll et al study, saw the heroin group 
disadvantaged). 
Only 57% of the total sample were still in treatment a year later, 59% of those who 
had chosen heroin compared with 48% of those who had chosen methadone. Ten of 
the 25 no longer in treatment had been discharged for disciplinary reasons rather than 
dropping out. Those who remained it treatment had average ending doses of 161mg in 
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the methadone group and 185mg in the heroin group. The main problems reported 
were discomfort while injecting in the methadone group, and too low dosage in the 
heroin group. The discomfort reported by those in the methadone group led 
researchers to question a previously held belief that a major advantage of prescribing 
injectable methadone was that clients would only have to inject once per day. This 
was clearly not the case, with clients reporting splitting the dose into two/three 
injections to reduce the clear discomfort experienced whilst injecting large amounts of 
methadone. 
At 3 months and 12 months, both groups exhibited major reductions in drug use, 
injecting and crime, and improvements in mental, physical and social functioning. 
There were no significant differences in treatment outcomes between the two groups - 
and any conclusions drawn from comparisons between the two are restricted because 
clients chose their treatment group rather than being randomly assigned to them. 
However, it is possible to conclude that as one of the criteria for selection onto the 
study was a previous failure to comply with oral methadone treatment, those clients 
who remained on either type of injectable prescription made significant and 
previously unseen improvements. 
The other two relevant studies focusing on heroin prescribing were conducted in 
Switzerland (1994-2000) and in The Netherlands (1998-2001). 
Various reports (Pernegeret at 1998; Uchtenhagen 1999; Rehm et al 2001) following 
eight years of heroin prescribing in Switzerland provide the most detailed and long 
term perspective on the features of heroin substitution prescribing. In 1994 the 
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Medical Prescription of Narcotics Programme (PROVE) was started, it began to be 
evaluated from 1996, and expanded in 1998. By 1998,1,060 people were being 
prescribed heroin atl 8 locations, including in prison. By 1999, nearly 2000 were 
being maintained on heroin prescriptions across 21 centres. (Rehm et a12001) This 
comprehensive range of reports included double-blind studies (drug not known to 
either doctor or patient), studies based on treatment assessment and patient choice, 
and studies involving random allocation to treatment groups. (Perneger et al 1998) 
Initial data were collected over three years on a cohort of 1,035 chronic heroin clients 
who had failed in drug-free or methadone substitution treatment programs, and who 
were prescribed heroin, morphine or methadone within a comprehensive care 
program at one of 17 outpatient centres. (Uchtenhagen 1999) Criteria for inclusion 
were being aged 20 years or older, two years of injectable heroin addiction despite 
repeated treatments, with marked health damage and social problems. Clients 
attended their outpatient centre three times a day to inject heroin under clinical 
supervision. The average daily dose prescribed was 474mg - clients tended to 
stabilise on 500-600 mgs of heroin per day, with no evidence of increasing tolerance. 
Indeed, this is similar to the plateau of opiate tolerance suggested by Parry (1992). 
Nearly a quarter also received methadone, and weekly counselling was compulsory. 
Retention in treatment was 89% at six months, 76% at 12 months, and 69% at 18 
months - most leavers went on to more progressive and less time consuming 
treatments. 
Of 385 clients who started before April 1995, detailed findings were reported for the 
237 (62%) who remained in treatment for 18 months. About 80% reported daily use 
of illegal heroin in the six months before treatment, compared to 3-16% by 1997; and 
32 
31% reported income from crime in the six months before treatment, compared to 5- 
18% by 1997. There were also reductions in use of cocaine and benzodiazepines, 
reductions in injection-related damage and mental disorder, and improvements in 
employment, housing and finances. The annual mortality rate was about 1% (many 
were probably due to pre-existing diseases, and none were overdoses), and only minor 
problems were reported in the community (eg. occasional diversion of heroin). 
These outcomes compare favourably with the outcomes for treatment clients in 
Britain after two years treatment (who were typically prescribed oral methadone), 
according to the 2001 NTORS five year follow up study. (Gossop et al 2001) Costs 
per treatment day were estimated at £20, while benefits (mainly from savings to the 
criminal justice system) were estimated at M. It was concluded that heroin 
maintenance has a positive effect on opiate clients and their social environment due to 
an improvement in health and social status and a significant decrease in drug-related 
delinquent behaviour. 
The only part of the Swiss study to utilize the random allocation of clients to different 
treatment options took place in Geneva. This study, randomly assigned 51 opiate 
clients; 27 to receive injectable heroin maintenance, while randomly assigning another 
24 opiate clients into a control group with a six month `waiting list' (most of whom 
(19) received oral methadone). (Perneger el al 1998) Clients in the experimental 
group were occasionally prescribed oral opiates (eg. for night-time withdrawals)., and 
all were still in treatment after six months. (21 of the control group were still on the 
waiting list receiving oral methadone) It was found that: 
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(1) none of the experimental group were using illicit heroin after six months in 
treatment, compared with half of the controls; 
(2) criminal income and spending on drugs fell to a tenth of pre-treatment levels for 
the experimental group, but remained at high levels in the control group; 
(3) mental and social functioning in the experimental group improved relative to the 
controls, though there were no differences in physical health between the two groups. 
(4) heroin was regarded as more `attractive' than methadone, and had fewer side- 
effects. 
Those clients in the experimental group were offered a comprehensive range of extra 
services, including counselling and general healthcare. Similar interventions and 
support were not offered to those on the waiting list receiving oral methadone, and 
this prevents researchers from attributing with any degree of reliability the various 
improvements solely to treatment regimes. 
The final (and by far the largest) randomised study focusing on heroin prescribing, or 
more specifically co-prescribing, took place in the Netherlands. 
In the Netherlands heroin prescribing was initially piloted on 50 opiate clients in July 
1998 - 25 in Amsterdam, and 25 in Rotterdam. In February 1999, the program was 
extended to include opiate clients in The Hague, Gronigen, Utrecht, and Heerlen. By 
1999,700-800 Dutch opiate clients were being prescribed heroin. (van den Brink et al 
1999) 
Between 1998 and 2001, The Central Committee on the Treatment of Heroin Addicts 
(CCBH 2002) selected 549 patients who were chronic treatment-resistant heroin 
clients previously prescribed methadone. Clients were randomly allocated to either 
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(1) none of the experimental group were using illicit heroin after six months in 
treatment, compared with half of the controls; 
(2) criminal income and spending on drugs fell to a tenth of pre-treatment levels for 
the experimental group, but remained at high levels in the control group; 
(3) mental and social functioning in the experimental group improved relative to the 
controls, though there were no differences in physical health between the two groups. 
(4) heroin was regarded as more `attractive' than methadone, and had fewer side- 
effects. 
Those clients in the experimental group were offered a comprehensive range of extra 
services, including counselling and general healthcare. Similar interventions and 
support were not offered to those on the waiting list receiving oral methadone, and 
this prevents researchers from attributing with any degree of reliability the various 
improvements solely to treatment regimes. 
The final (and by far the largest) randomised study focusing on heroin prescribing, or 
more specifically co-prescribing, took place in the Netherlands. 
In the Netherlands heroin prescribing was initially piloted on 50 opiate clients in July 
1998 - 25 in Amsterdam, and 25 in Rotterdam. In February 1999, the program was 
extended to include opiate clients in The Hague, Gronigen, Utrecht, and Heerlen. By 
1999,700-800 Dutch opiate clients were being prescribed heroin. (van den Brink et al 
1999) 
Between 1998 and 2001, The Central Committee on the Treatment of Heroin Addicts 
(CCBH 2002) selected 549 patients who were chronic treatment-resistant heroin 
clients previously prescribed methadone. Clients were randomly allocated to either 
34 
an experimental (heroin plus methadone) or control (wvaiting list & oral methadone 
only) group. The study compared the outcomes of 12 months co-prescription of oral 
methadone plus injectable or inhalable heroin, (the inhalable heroin was provided as 
powder, like street `gear', not in reefers as in the UK), with the outcomes of 12 
months of oral methadone alone. In the co-prescription group, methadone was 
prescribed to prevent withdrawal symptoms when prescribed heroin was not 
available. It was found that: 
(1) co-prescription of heroin and methadone was more effective than methadone 
alone, producing greater health benefits and improved continuation in treatment; 
(2) compared with methadone-only treatment, co-prescription produced no excess of 
serious medical problems or public order problems. 
Some of the clearest benefits to be seen were in the reported reduction in criminal 
activity, linking the Dutch study to current UK thinking regarding drug policy 
priorities, and in turn the priorities for attracting clients into treatment. 
1.4.2 Summarising the evidence 
Any summary of the evidence in favour of prescribing heroin must start by addressing 
the concerns of those who would seek to discredit it as an effective form of treatment. 
The main concerns, presented earlier in section 1.2.2, centre around three key areas: 
0 Risk of perpetuating the `career' of the opiate user by prescribing heroin rather 
than methadone 
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" Risk of leakage/diversion to the illicit market thus creating new users 
" Justifying the cost of diamorphine as opposed to methadone prescriptions 
Clearly selecting the most suitable clients to receive prescribed heroin is a crucial part 
of any research trial or resulting treatment programme. The five studies used slightly 
different recruitment criteria, with the Dutch study operating the strictest criteria 
including the requirement that clients must be currently in treatment, have had a 
minimum of five years heroin addiction and a daily injecting habit. The question of 
perpetuating a heroin habit by offering it on prescription is clearly affected by the 
dose of heroin available. In the UK studies the heroin dose was capped at the same 
level as the methadone dose - leading many clients, one third in the case of Metribian 
et al (1998,2001) to opt for a methadone prescription. Also in terms of perpetuating 
an injecting drug habit, the Swiss trials seem to suggest that with the appropriate 
follow up treatment programmes available, clients choose to leave the heroin 
programme when stable, to move away from the restrictions imposed including twice 
daily attendance, counselling, and supervised consumption. 
Supervised consumption was a feature of the Dutch and Swiss trials, but not the three 
UK studies, and it's a issue which may hold the key to convincing the sceptics that 
prescribing heroin could work for some clients, whilst at the same time not create new 
ones. The issue of leakage/dispersion is particularly relevant in the UK as it was this 
which was cited as one of the main reasons for the sharp increase in heroin 
availability in the 1960's. The evidence is fairly limited regarding dispersion and on- 
site supervised consumption would pose clear difficulties in some areas/situations, for 
example rural areas, or for clients who worked or had family responsibilities. Clinical 
guidelines issued by the Department of Health state that supervised consumption is a 
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recommenced and necessary precaution, which should be implemented during the 
early stages of an addicts treatment (DOH 1999). Supervised consumption is common 
in other countries but varies around the UK, where there is still no formal national 
policy 
In terms of cost, supervised consumption is identified as one of the areas, which 
inflate the overall price of prescribing heroin. Stimpson and Metribian (2003) estimate 
that it costs between £7,717-£9,691 per addict per year to prescribe (a supervised) 
injectable heroin script, compared to £2,800 for a methadone prescription (excluding 
supervised consumption) (see Table 1.8 below) 
Table 1.8: Estimated annual cost of prescribing heroin per patient in the UK 
Cost Per annum (£) 
Capital and revenue buildings and land, equipment, 
staff, supplies and services, site and agency overheads i. 1,872 
Supervised consumption for first 3 months 2.987 - 2,961 * 
Drug costs - assuming 175mg per day 4,858 
Total 7,717 - 9,691 
Notes: 
i. Netten and Curtis (2001) 
2. Strang et al (2000) 
* lower cost based on cost of supervising one injection of methadone per day; 
upper cost inflated pro-rata for three injections of heroin per day 
source: Stimpson and Metrebian (2003) Prescribing heroin: what is the evidence? 
Any consideration of the relative costs associated with prescribing heroin must also 
include the potential knock-on effects including costs incurred/saved by the criminal 
justice and health care systems. The Swiss trials also saw improved employment rates 
and increased productivity amongst those clients receiving heroin prescriptions. 
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Two other issues to consider when examining the effectiveness of heroin prescribing 
are; use of illicit drugs in addition to a heroin prescription, as compared to those 
receiving methadone; and the actual design of the studies themselves in terms of 
reliability, validity, random allocation of clients, use of control groups etc. 
Each of the five studies found a reduction in the levels of illicit drug use exhibited by 
those on heroin scripts, however not all the studies involved control groups, or pre- 
treatment stages, with which to compare this reduction. Illicit use was not eliminated 
in any of the studies. Only one of the UK studies was randomised (Hartnoll et al 
1980), as was the Dutch study - and especially in the case of the Dutch study, it was 
clear that the pragmatics and ethical considerations associated with allocating clients 
randomly to treatment groups were extremely complex and time consuming. The 
control and time constraints associated with clinical trials, in any area of treatment, 
might not easily translate into large scale `real world' treatment programmes. 
1.4.3 NTORS 
The National Treatment Outcome Research study (NTORS) was commissioned in 
1994 at the request of the Minister of Health. A prospective longitudinal study of 
clients in a range of treatment programmes across the UK, designed to reappraise the 
effectiveness of the national drug treatment strategy/ies. Clients (1,075) were 
recruited during the first six months of 1995, and interviewed at various points 
including intake, six months, one year, two years, five years etc. NTORS followed 
clients on residential and community methadone maintenance and reduction 
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programmes and did not therefore focus on heroin prescribing as a treatment option. 
However the methodological and ethical considerations it raises, (including the 
relative cost of treatments in terms of a reduction in criminal activities, and the 
difficulties of clients moving between treatment programmes/scripts), gives those 
interested in heroin substitution treatment and its evaluation valuable bench marks 
from which to begin to make meaningful comparisons. 
NTORS conducted a one year follow up study of 478 clients taking part in drug 
prescribing programmes in 1996 and found that regular use of opiates had fallen from 
86% to 55%, and offending (all crimes) had fallen from 62% to 40%. 
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Chapter Two - INTRODUCTION TO THE STUDY 
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Chapter Two - INTRODUCTION TO THE STUDY 
This chapter will introduce the study by placing it firstly into a `prescription 
context'(mid 1990's), and then into a regional context. In many ways the UK still has 
a rather fragmented approach to drug treatment services, (and this was certainly the 
case in 1996-98), which can often differ significantly from one region to another. 
(Although this is changing with the establishment of various national agencies eg the 
National Treatment Agency). 
2.1. Political & Policy context of the study: National prescription patterns 
Two key studies examined the prescribing patterns involved in the treatment of 
problem drug use in Britain in the mid 1990's. The first of these presented reported on 
the prescribing of agencies/doctors, the second (in two parts) reports on the dispensing 
of pharmacies. 
Sell et al (1997) reported a survey of all drug treatment agencies providing a 
prescribing service in England & Wales from March to June 1995 (using SCODA and 
DOH drug agency listings). Of the 172 treatment agencies surveyed' 105 (61 %) 
responded. Respondents were typically psychiatrists with addiction specialisms. The 
table below shows one third of those agencies that responded were currently 
prescribing heroin to, on average, nine clients per agency. 
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Table 2.1: Percentage of agencies with Home Office Licences to prescribe 
opiates, March-June 1995 
HEROIN DIPIPANONE COCAINE 
Ever applied for license to prescribe 44% 15% 7% 
Current license to prescribe 43% 12% 5% 
Actually prescribing at present 33% 8% 4% 
Median duration 5 years 2.5 years 1 year 
Mean number of scripted patients 9.2 .... 
Daily dose ranges - min-max 10-1,000mg 10-150mg 
- median 30-200mg 30-70mg 
source ; Sell et al (1997) Prescription of diamorphine, dipipanone and cocaine in 
England and Wales. Drug and Alcohol Review, 16,221-226. 
(note - dipipanone is a synthetic opiate used as a major pain killer, trade name 
Dicanol) 
A large national survey of one in four of the 10,616 community pharmacies in 
England & Wales was conducted in 1995 (75% response rate - 1,984 pharmacies). 
Half (50%) were dispensing controlled drugs to an estimated 30,000 problem drug 
users (PDU's) (mean of 5.9 per pharmacy) - this compared with 23% of pharmacies 
dispensing to an estimated 7,700 IDUs in 1988 (mean of 3.5 per pharmacy). (Sheridan 
et al 1996; Strang et al 1997) 
Overall, 92% of prescriptions to clients were for methadone, 4% for amphetamines, 
2% for heroin, 2% for other opiates, and less than 1% for other controlled drugs. In 
short, 96% of prescriptions were for opiates (3,486) - of these, 96% were for 
methadone, 1.7% were for heroin, and 2.3% were for other opiates. The table below 
shows that the mean dose of methadone prescribed was 47mg - this ranged from a 
mean 44 mg for oral methadone from NHS doctors, to 118 mg for methadone 
ampoules from private doctors. 
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Table 2.2: Mean dose prescribed by UK Community Pharmacies 1995 
HEROIN METHADONE 
FORMS 
Tablets 16% 11% 
Ampoules 75% 9% 
Liquid 8% 79% 
Reefer 2% <1% 
DOSES 
Mean 175 mg 47 mg 
Median 130 mg 40 mg 
Range 10-500 mg 2-300 mg 
Interquar- 
tile range 60-270 mg 30-60 mg 
AMPHETAMINE 
73% 
3% 
24% 
source: Sheridan et al 1996; Strang et al 1997 
2.2. The North West Region 
There have been various changes to the geographical and political make up of the 
North West Region of England over the last 30 years, including changes to the 
organisation and delivery of drug services. At the time of this study, the UK 
Governments Department of Health had delegated control of health services in 
England and Wales to 15 Regional Health Authorities. The Mersey Regional Health 
Authority covered the counties of Merseyside and Cheshire, each of which was 
divided into five health districts. (Newcombe 1989) 
(It is perhaps worth mentioning at this point that specially licensed General 
Practioners (GP's) who worked at drug dependency units could only prescribe opiates 
under the direction of the consultant psychiatrist. As such, the type of prescribing 
available across DDU's nationally varied depending on the policies of the individual 
psychiatrist. ) 
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2.2.1 Prescription Patterns in the North West Region. 1995-2000 
As stated above, prescription availability varies across the country according to a 
variety of factors including the prevailing practices of the consultant psychiatrist 
responsible for each district health authority. The North West Region of England 
covers Lancashire, Cheshire, Merseyside, Manchester and Greater Manchester. For 
the five years 1995 - 2000, the following prescription figures were collated for the 
Region; 
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Table 2.3: prescribing, action for new clients in north west region, 1995-2000 
(drug misuse database) 
1995 1996 1997 1998 1999 2000 
Valid episodes 4048 7483 7002 7113 6591 7244 
METHADONE 2736 5979 5132 5008 4391 4774 
Mixture 2661 5517 4965 4605 4270 4630 
Amps 27 140 143 75 87 94 
Tablets 11 39 17 24 6 4 
Reefers 3 1 7 6 2 1 
Unspecified 34 282 79 298 26 45 
DIAMORPHINE 22 9 23 24 9 11 
Amps 8 0 0 1 3 1 
Reefers 5 0 4 0 0 0 
Unspecified 9 9 19 23 6 10 
OTHER OPIATES 298 119 170 196 214 265 
Dihydrocodeine 275 97 161 185 178 211 
Buprenorphine 2 2 0 1 25 45 
Morphine 3 4 2 2 1 3 
Codeine 2 2 2 1 4 1 
Opiate compounds - 13 7 2 4 6 4 
Unspecified/other 5 9 3 4 0 1 
STIMULANTS 16 61 45 37 27 24 
Dexamphetamine 14 55 40 30 27 24 
Methamphetamine 1 0 1 1 0 0 
Unspecified amphets 1 5 2 6 0 0 
Cocaine 0 1 2 0 0 0 
sources : University of Liverpool and University of Manchester 
(1996,1997); Liverpool John Moores University and University 
of Manchester (1998,1999,2000,2001) 
note - such as Distalgesic (dextropropoxyphene) 
In terms of prescribing trends, the data in Table 2.3 would suggest the following 
(a) reefer scripts and heroin scripts appear to have been phased out, particularly after 
1998 (eg. a total of just 3 reefer scripts - all methadone - were given in 1999 and 
2000) - It is presumbed, this trend is related to the departure of the consultant 
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psychiatrist, Dr. John Marks in 1998 (once he had left, the new consultants were not 
prepared to offer reefers to new clients, and heroin scripts generally dwindled). This 
trend is clearly illustrated in the clinic data presented in section 2.2.4; 
(b) the second most common script, surprisingly, is dihydrocodeine - this was largely 
due to a 'fashion' at the time among Lancashire treatment agencies to prescribe 
DF118s instead of methadone to some clients. 
Table 2.4 below indicates that at the time of data collection for this study (1995- 
1997), the region experienced a sharp fluctuation in the numbers of clients presenting 
at the DDU's, ranging from the lowest in the five-year period to the highest. The mid 
to late 1990's was a period of significant flux, locally and nationally. With so much 
control of prescribing policy given to individual consultant psychiatrists, it would 
always be the case that the departure of John Marks, a strong supporter of flexible 
prescribing, (including the prescription of heroin) in 1998, would have a `knock-on 
effect' on the regions prescription patterns. Nationally, the Labour Party won the 1997 
general election, and quickly mobilised its 10-year drugs strategy `Tackling Drugs to 
Build a Better Britain'. 
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Table 2.4: methadone prescribing regime for new clients in north west region, 
1995-2000 (drug misuse database) 
1995 1996 1997 1998 1999 2000 
Valid episodes 2727 5246 4685 4539 3966 4404 
Reducing dose 1219 2943 2651 2457 2118 2156 
Maintenance 354 564 470 480 448 680 
Not known 603 1739 1564 1422 1400 1568 
sources : University of Liverpool and University of Manchester 
(1996,1997); Liverpool John Moores University and University 
of Manchester (1998,1999,2000,2001) 
2.2.2 North West of England; Client data 1995-1997 
The data for the study reported here were collected between August 1995 and 
February 1997 at two clinics in Cheshire. The prevailing numbers of clients, new 
clients, heroin and methadone users, referral sources etc in the North West of England 
;' as a whole were recorded over that period and are as follows; 
1995 
10,429 new agency episodes of presenting problem drug misuse were reported from 
agencies in the NW. This represented 8,488 individuals of whom 52% (4415) were 
`new' to services. Fifty seven percent of all episodes were reported by statutory 
community based drug services. Seventy five percent of those reported were male. 
Eighty four percent were unemployed. Seventy five percent (6,372) were heroin users, 
and of those 84% (5,328) were primary, and 16% (1,044) were secondary users. 
Methadone was the second most commonly reported drug, being used by 3,616 (43%) 
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individuals, 47% of whom reported using methadone as their primary drug. 
(University of Liverpool and University of Manchester, 1996) 
1996 
(these figures are most relevant to the data presented in this study as most of it was 
collected during 1996) 
During 1996 10,499 new agency episodes of presenting problem drug misuse were 
reported in the NW. This represented 8,665 individuals of whom 47% were `new' to 
services. (These figures were very similar to 1995). (again) Fifty seven percent of all 
episodes were reported by statutory community based drug services. Seventy four 
percent of those reported were male. Seventy seven percent were heroin users, and 
almost half (45%) were using methadone, usually (70%) prescribed. Just under half 
(48%) of those reported had injected a drug in the previous four weeks. Of these 12% 
acknowledged that they had also recently shared injecting equipment. The number 
admitting sharing was 4% greater than in 1995. 
(University of Manchester and University of Liverpool, 1997) 
1997 
Fewer episodes and individual users were reported than in the previous two years. 
9,177 new agency episodes of presenting problem drug misuse were reported, relating 
to 7,897 individuals of whom 46% (3,634) were `new' to services. Sixty six percent of 
all episodes were reported by statutory community based drug services. Seventy two 
percent of those reported were male. Seventy six percent were heroin users, and of 
those 62% (4,897) were primary, and 38% (1,068) were secondary users. The level of 
heroin use in 1997 (76%) was very similar to that in 1995 (75%). Most heroin users 
48 
were injecting (57%). A total of 3,548 methadone users were reported, 74% of whom 
were using prescribed methadone. 
(University of Liverpool and University of Manchester, 1998) 
2.2.3 The clinics; location and services 
The two community drug teams involved in this study are located in the Cheshire 
districts of Widnes and Warrington. The same consultant psychiatrist, Dr John Marks, 
had overall responsibility for the prescribing of opiates (and other drugs) at both 
clinics. 
Both clinics were located in the community; the Widnes clinic was in the town centre, 
based in offices above an Insurance company, the Warrington clinic was based in a 
converted town house close to the railway station. At each clinic the staff included a 
manager, probation officer, social worker, community nurse, an assistant to the 
manager and a secretary. A small team of specialist GP's employed on a sessional 
basis supported the consultant psychiatrist, and each clinic also employed three/four 
outreach workers/counsellors. 
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2.2.4 The clinics; prescription trends 
Both clinics prescribed the following; 
Ampoules - methadone, heroin, morphine, amphetamine, cocaine. 
Mixture/Syrup - methadone, dipipanone, amphetamine, cocaine. 
Tablets - methadone, morphine, cannabis 
Reefers - methadone, heroin, morphine, amphetamine, cocaine 
(Marks 1991) 
According to client lists produced by the Cheshire Family Health Services Authority 
in November 1997, there were 132 clients registered and receiving prescriptions from 
the Widnes clinic and 182 from the Warrington clinic. (314 clients in total) 
For the financial year ending April 1996, in-house CDT figures showed the following 
trends in prescribing for each clinic; 
Widnes CDT 
Clients receiving methadone only rose from 28.75% in April 1995, to 72% in April 
1996. Clients receiving diamorphine only fell from 27% in April `95 to 8% in April 
`96. Clients prescribed a combination of the two fell from 30.5% in January `96 to 
20% in April `96 
Warrington CDT. 
Clients receiving methadone only, rose from 59% in April 1995, to 94% in April 
1996. Clients receiving diamorphine only fell from 11 % in April `95 to 1% in April 
50 
`96. Clients prescribed a combination of the two fell from 30% in April `96 to 5% in 
April `96. 
2.2.5 Pilot Study; Injectable and Smokable opiates 
From 1989, the drug dependency units in Widnes and Warrington began prescribing 
injectable and smokable alternatives ('reefers'), to those clients registering with a 
history of long term or injecting drug use. These alternatives included heroin, 
methadone, (and less frequently) amphetamine and cocaine. The reefers were 
produced by a local pharmaceutical company in Liverpool and distributed to local 
pharmacies. Herbal or nicotine cigarettes were injected with a solution of the 
particular drug (dissolved in chloroform), most commonly diamorphine or methadone 
hydrochloride. The chloroform would evaporate after a few minutes, leaving only the 
dissolved drug and a slight green stain on the cigarette paper behind. This green stain 
would distinguish the reefer from a standard cigarette and help prevent any confusion 
between the two. Clients were prescribed injectables and/or reefers either in 
conjunction with other drugs, or as a complete replacement. (see Atlantic Project 
video, 1991) 
It was noted that up to two thirds of the drug in a reefer may be lost due to either poor 
inhalation techniques or side-stream smoke, and for this reason clients on reefers were 
prescribed higher doses than those on injectables and oral mixture. For roughly 
equivalent prescriptions, the relevant prescription costs per year were £100-£200 for 
oral methadone, £300-£600 for reefers, and £1000-£2000 for injectable opiates. 
(Marks et al 1991) 
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Many drug users accepted prescribed ampoules or smokables as an attractive, realistic 
and sustainable alternative to illicit injecting. Previously, clients not wanting 
detoxification were almost uniformly offered oral methadone (or occasionally) 
diamorphine as the only alternative to injecting heroin. For an addict prescribed this 
oral substitute, the absence of the `rush' (fast, intense entry into intoxication) 
associated with injecting often led to dissatisfaction and a search for `black market' 
excitement, sometimes financed by selling part or their entire oral substitute. (Marks 
et al 1991) 
Prescribing smokable alternatives resulted in the user experiencing the `rush' whilst 
avoiding the transmission of HIV, and risk of potentially fatal poor injecting 
techniques. It was also suggested that the diamorphine reefers, with a shorter `half- 
life', were less addictive (and therefore easier to eventually withdraw from), than the 
oral methadone syrup previously offered. (Marks, Palombella & Newcombe, 1991) 
The driving force behind this initiative was a desire to help clients reduce the risks 
associated with illicit injecting (particularly H. I. V. infection), and to encourage those 
illicit drug users (previously not in contact with any agency) to make contact and 
secure the associated help and support (Marks et al, 1991; Marks & Palombella, 
1990). 
Based at a drug dependency unit in Cheshire, Newcombe (1989) conducted an initial 
small scale pilot study involving 20 clients in four different prescription groups. The 
two IVs were type of drug (heroin or methadone) and form of drug (reefer or 
mixture), with five clients in each of the four conditions (heroin 
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reefer, heroin mixture, meth reefer, meth mixture). Initial findings indicated some 
success, particularly in relation to reefers being a viable alternative for reducing illicit 
injecting levels and levels of criminal behaviour. A series of follow up interviews 
with the clients seemed to suggest that certain combined scripts (namely 
meth mixture and heroin reefers together) were associated with better 
crime/drug use outcomes than single scripts? (Funding for the main study was not 
secured) (Newcombe 1989) 
2.3 Research Rationale and Aims 
Although Britain and `the British System' has played a significant part in the history 
of diamorphine, there have been surprisingly few UK research studies specifically 
focused on its viability as a treatment option for problem drug users. Those who 
question its viability cite three main areas of concern; risk of diversion, increased 
costs, and risk of prolonging an injecting drug `career'. Those who support the use of 
diamorphine offer examples of good practice to challenge these concerns, and cite 
findings from (limited) previous research as evidence to support their claims that 
diamorphine has its place in the treatment range. 
It appeared (and continues to appear to be the case) that medical practitioners and 
government policy makers were at odds in terms priorities; the medics prioritising the 
need of the individual to be drug free, and the policy makers prioritising the needs of 
the wider community in terms of the reduction of crime. An effective treatment 
strategy would need the support of both groups, and would therefore have to address 
clinical needs and societal needs. 
53 
This study explored the effectiveness of diamorphine/heroin as a treatment option for 
those problem drug users for whom, for a variety of reasons, it may have been better 
suited than the traditional substitution drug; methadone. "Effectiveness" was assessed 
across several criteria including use of illicit drugs, self-efficacy, criminal activity and 
drug-related time demands. 
Aims 
The project aimed to assess several inter-linked questions within a harm reduction 
framework. Three key areas and their association with heroin prescribing will be 
addressed; levels of criminal activity, levels of illicit drug use, and a range of client 
held perceptions regarding coping/quality of life etc. 
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3.1 Design 
Apart from two demographic variables (gender and age), all variables fall into three 
categories - i) Type of prescription (script type), ii) Drug consumption (drug use), 
and iii) Criminal behaviour (crime) - each of which can be divided into primary and 
secondary variables, as well as into `behaviour' and `perceptions' items. 
(Question numbers refer to the relevant item/s on the Research Questionnaire, which 
can be found in Appendix 1. ) 
3.1.1 Script Type 
Script type is based on three primary categorisations of prescription information: 
form (ampoules/mixture/reefers), drug (methadone, /heroin/other), and form&drug 
combined (heroin reefers, methadone mixture, heroin ampoules etc). 
Excluding various rare/unusual scripts (eg cocaine, methadone tablets) three script- 
type variables are as follows: 
1. Form only: a. Script includes ampoules (yes/no), b. Script includes reefers 
(yes/no), and c. Script includes mixture (yes/no) 
2. Drug only: Script contains methadone only (n=63), heroin only (n=36) and 
heroin & methadone only (n=16) 
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3a. Specific script: (3 main script combination types): methadone mixture (MM) 
(sole & combined), heroin reefers (HR) (sole & combined), and MM with HR 
(sole & combined) 
3b. Specific Script: as (3a), but, due to small numbers, excluding MM&HR 
(n=10), leaving MM (n=51) and HR (n=25) 
Five secondary script variables include: dose (in milligrams)- question 1, duration of 
time on that particular script (months) - q2, who made the decision to receive current 
script (client +/or staff) - q4, perceived satisfaction with current script (5-point rating 
scale) - q3, and perceived desire to change current script (incl. how & why client 
would like script to change) - q5. 
3.1.2 Drug use 
Drug use is based on one prima, y variable - the use/non-use of nine types of drugs - 
(cannabis, alcohol, nicotine, heroin, diamorphine, methadone, amphetamine, cocaine 
and benzodiazapines). This variable was re-coded from questions 6&7 which asked 
about the frequency with which the drug was taken. 
`Drug use' data is also based on 9 secondary variables: 
1. amount consumed (x 9 drugs as above) - questions 6&7, 
2. frequency with which the drug was taken (x 9 drugs as above) - q's 6&7, 
3. spending per month (x 6 drugs above - not alcohol/cannabis/nicotine) - ql O, 
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4. injecting - drug (whathvhich drugs injected in the last month) - q8a 
5. injecting - frequency (injected how often in the last month) - q8b 
6. source - where are illicit drugs acquired from - q9 
7. financing - are wages/benefits used to pay/partly pay - ql 1 
8. time-taken - with drug use (including crime) per day - q15 
9. perceived causes of use - main factors causing use -q 18 
Two additional variables are also examined in relation to drug use. These are i) 
perceived coping with life now (q16), and ii) perceived quality of life compared to 
one month ago (ql7a) (both measured on 5-point rating scale) 
3.1.3 Crime 
Crime is based on one primary variable - whether the user did/didn't do seven 
aquisitive crimes (burglary, shoplifting, dealing script, dealing street drugs, 
prostitution, theft from family, and other thefts) - this variable was re-coded from 
question 12 which asked about frequency of crimes committed. 
Three secondary crime variables include: frequency (of committing the crime - 
ranging from every day to not in the past month - q12), perceived causes (why this 
crime was carried out - q13), and perceived script-crime link (would a change in 
script affect criminal behaviour - q14) 
Using the abbreviated labels explained above, the variables can be summarised in the 
table below; 
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Table 3.1: Summary of Variables 
BEHAVIOUR PERCEPTIONS etc. 
SCRIPT Type (x4) Dose Duration Decision Satisfaction/Change-script 
DRUG USE Type (9 drugs) Amounts/Frequency/Spending Causes/Coping/Quality 
Injecting/Source/Financing/Time-taken 
CRIME Type (7 crimes) Frequency Reasons/Script-crime 
3.1.4 Research Questions 
The main research question and source of most statistical comparisons is; does the 
type of prescription affect illicit drug use, criminal activity, or related 
perceptions/attributions among treatment clients? 
Independent variable Groups of dependent variables 
Script-type - Drug consumption 
- Criminal activity 
4 Perceptions/Attributions about drugs/crime 
Due to the limited and conflicting evidence all statistical tests were 2-tailed. 
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3.2 Participants 
One hundred and thirty three registered drug users based at one of two drug 
dependency units in the North West of England; Warrington and Widnes, were 
recruited to the study via convenience/opportunity sampling. The average age of the 
sample was 30, with a range of 20-49 years. Clients were recruited over an 18 month 
period between August 1995 and February 1997, in three phases; August 1995- 
October 1995 (50 clients), April 1996-June 1996 (36 clients), and December 1996- 
February 1997 (47 clients). Data were gathered in three phases for two reasons; 1. the 
clinics were relatively small and the researcher had to wait for new referrals to be 
made, and 2. external factors, unconnected with the study, restricted the time available 
to carry out the (often time consuming) interviews. 
Of the one hundred and thirty three clients, 75% were male, 24% were female (in 
error two clients were not recorded). The drug dependency units had a total of 314 
registered clients, 182 at Warrington and 132 at Widnes. (Clinic records November 
28 `h 1996) Of the total registered, 73% were male (229) and 27% were female (85). 
On the basis of these figures, it was estimated that about 40% of clients registered at 
the two DDU's during the study period participated in the research. 
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3.3 Procedure 
3.3.1 Pilot Study 
Between January 1994 and March 1994,57 registered drug users, based at the same 
two drug dependency units, completed a one hour semi-structured, questionnaire- 
based interview, answering questions relating to their past and current, behaviour and 
attitudes. 
The forty five men and twelve women, (with a mean age of 31), divided into three 
groups according to the prescription they were receiving; - an exclusively or 
predominantly smokable prescription (N=23,40%), exclusively or predominantly 
injectable prescription (N=16,28%) and an exclusively or predominantly oral 
methadone prescription (N=18,32%). The sample was made up of clients who had 
been registered for between 3 months and 14 years, with a mean registration period of 
4.5 years. Respondents were contacted by opportunistic sampling. 
Differences were apparent, both across prescription groups (for example those on 
injectables compared with those on smokables), and across the time periods of before 
and after registration at the clinic. 
Initial conclusions were drawn in three main areas; Firstly, initial analysis suggests 
that different prescription regimes did have significant effects on the subsequent 
prevalence and frequency of unhealthy and anti-social behaviours. Secondly, it is 
clear that, for the majority of those clients interviewed, registering at a drug 
dependency clinic had a positive effect on their quality of life across a number of 
different levels. Thirdly, prescribing practice continues to be heavily influenced by the 
prevailing political and economic climate of the area/time, and it is this factor in 
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particular which may prove to be the key to the success or otherwise of future service 
provision. 
Many questions and response formats were also modified as a result of feedback 
during the pilot study. 
`\ 
(Shortly after the pilot study, the project and degree registration was officially 
suspended due to a serious road traffic accident, hence the gap between pilot study 
and main study) 
3.3.2 Main Study 
After consultations with a number of clients, clinic staff, and a review of the available 
literature and pilot study methods, it was decided to utilize the self-report method of a 
questionnaire-based interview to elicit the required information. (see Harrison 1995) 
Each client was asked to complete a self-report questionnaire during a forty-minute 
interview. (Appendix 1. ). Each interview was conducted in an environment of the 
clients choosing, invariably the waiting area of the clinic or a nearby side room. Every 
effort was made by the researcher to distance herself from the day to day running of 
the clinic or management of the client's `script. When working with clients in a 
manner which assumes a certain amount of risk related disclosure, however minimal 
in reality, it is clearly important to quickly establish an egalitarian relationship rather 
than a hierarchical one. (Springer 1991) At no time during the clinic session did the 
researcher enter the DDU, she remained in the waiting area with any clients arriving 
to attend various groups/appointments. 
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It is commonly held that research which utilizes rigorous procedures to protect 
respondent anonymity and confidentiality produces the best possible estimates of both 
legal and illicit drug use. With the rules applied in the clinic setting, in particular the 
immediate cessation of a prescription should `top-up' illicit use be detected, this 
confidentiality became doubly crucial. Classical utility theory assumes that 
respondent's decisions on how accurately to respond to sensitive questions on drug 
use is based on the perceived risks if they provide truthful responses and the perceived 
loss associated with possible outcomes if the information were known. (Harrison 
1995). 
All clients were reassured that none of their responses would be seen or reported to 
clinic staff, no names were recorded and all completed interview data was 
taken/posted directly to the university following the session. 
3.4 Research Instrument/Materials 
The self-report questionnaire is divided into four sections; a) questions about 
prescriptions, b) questions about drugs used in addition to prescription, c) questions 
related to criminal activities, and d) questions related to quality of life in relation to 
current drug use. Specifically, these sections included items related to basic 
demographic data, current prescription type and form, perceptions/feelings and 
attributions, illicit drug use history and currently, criminal activities and frequency, 
injecting behaviour, and additional specific items relating to source and funding of 
illicit drugs. The questionnaire can be found in Appendix 1. 
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Questions were formulated according to the four key variable areas: prescriptions, 
drug consumption, crime, and perceptions/attributions. Whilst the range of possible 
topics is quite clearly vast, it was decided to maintain focus on these three throughout, 
to maximise the relevance of the study to the key areas of controversy surrounding the 
issue of heroin prescribing. 
Validity. In general surveys of drug use are often criticised on the assumption that 
respondents underreport the true extent of their substance use. However validation 
studies conducted in the early 1990's involving known samples of drug users, 
correlating self report data with urinalysis techniques showed that drug use was fairly 
accurately reported. (Harrison 1995) 
Response formats included open-ended (13 questions), rating scales (3 questions) and 
multiple choice (25 questions). Rating scales were 5-point Likert scales, with each 
point numbered and labelled. 
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3.5 Methods of Analysis 
In analysing the data, the researcher adopted a strict view of all rating scales as 
ordinal rather than interval measurement: In terms of the rating scales, 
consistent use of non parametric analysis was employed to avoid `forcing' the issue to 
`create' significant findings by using parametric equivalents. 
Descriptive analyses included measures of central tendency, measures of dispersion, 
and percentage figures. Inferential analyses focused on tests of differences between 
script conditions (Mann-Whitney, Chi Square, t-tests, 1-way ANOVA etc) and 
correlation of some interval variables (eg age, duration on script). 
3.6 Ethics 
In line with BPS Ethical Guidelines, all the clients were informed about the content of 
the questionnaires before giving their consent to take part in the study. Clients were 
also told that the questionnaires would be completed anonymously. For this reason 
clients were made aware that they were free to withdraw from the study at any time 
until they submitted their questionnaire, after this time their questionnaire would be 
untraceable. 
Participation was entirely voluntary, and had no bearing on their attendance at the 
clinic or the prescription they would receive. Approval for the study (pilot and main 
study) was given by the multidisciplinary management team responsible for both 
clinics, under the guidance of the Consultant Psychiatrist. 
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Chapter Four - FINDINGS 
Findings will be presented in five sub sections as follows; Characteristics of the 
sample (basic demographic information); Types of prescription (categorised for 
analysis purposes, and also including duration of `script' data); Client perceptions and 
attributions (including self efficacy and quality of life); Illicit drug use (including the 
use of `top up' drugs and their cost); and-Criminal activity (categorised in terms of 
type and frequency of crime). Illicit drug use and Criminal activity both focused on 
reported behaviour in the month prior to interview. 
4.1 Characteristics of sample 
The sample was made up of 133 clients registered at one of two drug dependency 
units (DDU's) in the North West of England, and data was collected in three phases 
between August 1995 and February 1997. One hundred clients were male (75%), 31 
female (24%), and the gender of two was not known. The average age of the sample 
was 30 years, with a range of 20 to 49. 
4.2 Types of prescription. 
The sample received a total of 29 different types of prescription based on a 
combination of form (ampoules, mixture, reefers, tablets) and drug type (heroin, 
methadone etc). The most common of these were methadone mixture 38 (29%), 
heroin reefers 18 (14%), heroin ampoules 12 (9%), methadone mixture and heroin 
reefers 8 (6%), methadone reefers 6 (5%), and methadone ampoules 6 (5%). 
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For analysis purposes the prescriptions were categorised in 3 different ways: (1) three 
main forms, (ampoules, mixture and reefers); (2) three main types of drugs (heroin, 
methadone and heroin & methadone together); and (3) three main combinations 
(methadone mixture, heroin reefers and heroin ampoules). 
Twenty three percent of the sample received part/all of their prescription in the form 
of ampoules; 52% were receiving heroin, 32% received methadone, 6% received 
methadone and heroin, and three were unspecified. Fifty five percent of the sample 
received part/all of their prescription in the form of mixture; 3% were receiving 
heroin, 83% received methadone, and ten were unspecified. Thirty six percent of the 
sample received part/all of their prescription in the form of reefers; 67% were 
receiving heroin, 15% received methadone, 6% received methadone and heroin, and 
six were unspecified. (see Table 4.1 below). 
Of the 14 clients who received "other" prescriptions; 43% received benzodiazapines, 
29% received methadone tablets, 7% received Dicanol, one person received morphine 
sulphate, one anti-depressants, and one was unspecified. 
The mean time clients had been receiving a prescription was a little under 3 years (35 
months), with a range of one month to 21 years. 
(As expected) There was a highly significant positive correlation between age and 
number of months on script. (r=+. 34, p<0.001, n= 122) 
When focusing on prescriptions categorised by type of drug; 47% received 
methadone only, 27% received heroin only, and 12% received a combination of 
methadone and heroin. When focusing on the three main prescriptions by type and 
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form: 38% received methadone mixture, 19% received heroin reefers, 8% received a 
J 
combination of methadone mixture and heroin reefers. 
The range of prescriptions - based on the drug prescribed and its form (or method of 
use) - are summarised in Table 4.1 below: 
Table 4.1: Numbers (%) of clients getting each of 12 types of script, based on 
combination of three forms and four drug types 
Ampoules Reefers Mixture 
Methadone 10 (32) 7 (15) 61(84) 
Heroin 16(52) 32(67) 2 (3) 
Meth. & Heroin 2 (7) 3 (6) 0 (-) 
Unspecified 3 (10) 6 (13) 10 (14) 
TOTAL 31 48 73 
When interpreting this table, it is important to note that some clients receive more 
than one script-form, eg. reefers and mixture; while some receive more than one drug 
(eg. heroin and methadone). 
In short, clients prescribed ampoules and clients prescribed reefers are similar on their 
`drug' profile - most received heroin, some methadone - while those getting mixture 
were far more likely to be prescribed methadone, and fairly unlikely to be prescribed 
heroin. 
If the `unspecified' and multiple-drug cases are removed from the analysis, there are 
six remaining categories of prescription - the mean daily doses for each of these is 
shown in Table 4.2: 
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Table 4.2: Mean daily doses (mg) involved in each of the six main tunes of 
prescription 
Methadone 
Heroin 
Ampoules 
Mean SD N 
96 35 10 
203 157 15 
Reefers 
Mean SD N 
244 147 7 
430 196 29 
Mixture 
Mean SD N 
60 28 54 
90 14 2 
Some clients received more than one drug, or different forms of a drug, and so are 
represented by more than one script type in Table 4.2. However, it is still possible to 
examine prescribing trends across the script types; for instance, among those on 
ampoules, those getting heroin were prescribed twice as much as those getting 
methadone. There is a similar ratio for reefers (almost 2: 1), but this is less pronounced 
for mixture (1.5: 1). This reflects the higher potency of methadone compared with 
heroin. 
As mentioned in the Introduction, it is usual that reefer clients are prescribed doses 
two to three times higher than those for ampoule clients because it is assumed by 
clinic staff that up to half of the drug is lost through sidestream smoke etc. 
Two of the main specific drug/form prescriptions of interest in this particular study 
were methadone mixture (MM) and heroin reefers (HR). The following table gives a 
breakdown of figures for these two types of script, either alone or with others; 
Table 4.3: Number (%) of people on two main specific scripts (MM & HR) who 
were on that drug alone or another drug too 
This script With With other 
alone HR/MM eg. amps TOTAL 
Meth mixture 38(62) 10(16) 13(21) 61 
Heroin reefers 18 (51) 10 (29) 7 (20) 35 
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Focusing on the two main specific script groups above (MM and HR) two statistical 
tests were carried out for age and gender; 
The differences in age between the different script groups were non-significant (mean 
of 29 and 30 years respectively). 
But the gender difference was highly significant - 96% of heroin reefer clients were 
male compared with 65% of methadone mixture clients. (Chi-Square (YC) = 6.79, df 
= 1, p<. Ol) 
(These figures will be discussed further in relation to section 4.5 `Criminal Activity', 
and in particular the shoplifting and prostitution results) 
This gender bias is apparent when we look at the sample as a whole, 24% of which 
are female. Thirty five percent of methadone mixture clients are female, compared 
with just 4% of heroin reefer clients. 
4.3 Client Perceptions and attributions. 
Of the 131 clients who responded when asked about their perceived quality of life 
currently as compared with one month ago, 20% replied that it was worse or a lot 
worse, 47% stated that it was no different, and 23% indicated that it was better or a lot 
better. (Of the half who indicated "no difference", many may have been in treatment 
for several months/years, and improvements may already have occurred). When asked 
to cite reasons for any changes in life quality, the three main causes were being 
prescribed methadone (11%), "prescription not large enough/has been reduced" 
(19%), and "drugs/drug use generally" (11%). 
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When asked to describe the main cause/causes of their current drug use over half gave 
one or more of three reasons: 21% cited addiction/dependence, 19% stated that they 
were unemployed or had nothing to do, and 11 % indicated limited clinic treatment 
policies/practices. 
Regarding satisfaction with prescriptions, 39% of the total sample reported being 
unhappy with their prescription, and 44% reported being happy. In addition, 56% 
clients indicated that if they had a choice they would like to see their script altered, in 
the main by either increasing their existing dose of smokable diamorphine (15%), or 
by changing to a smokable diamorphine prescription (29%). 
The three main reasons cited for changing their prescription were to succeed in the 
treatment programme (24%), to stay off street drugs (37%), and because methadone 
made them ill (21%). 
An assessment was made of whether there were any significant associations between 
script type and respondents perceptions and attributions, namely; satisfaction with 
script, self-efficacy/coping etc, and perceived quality of life. 
Assumptions for parametric testing were generally not met by the data, so non- 
parametric (Mann-Whitney) testing was justified. (In each of the following statement 
of findings, the independent variable is underlined, the dependent variable is 
presented in italics, and relevant statistics are presented in brackets). 
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There were 4 significant effects: 
1. Clients whose scripts included oral drugs (mixture) were significantly less happy 
with their script compared with other clients (mainly using amps and/or reefers) - 2.7 
compared with 3.9 (U = 153.5, p<. 002) 
2. Clients on methadone mixture were significantly less happy with their scripts 
compared with clients on heroin reefers - 2.4 compared with 3.6 (U = 58.5, p<. 02) 
3. Clients whose scripts included injectable drugs (ampoules) perceived themselves as 
significantly more able to cope with life compared with other clients (mainly on 
mixture and/or reefers) - 3.9 compared with 3.1 (U =120.5, p<. 02) 
4. Clients whose scripts included injectable drugs (ampoules) perceived their quality 
of life, compared with one month ago, as significantly more improved compared with 
other clients (mainly on mixture and/or reefers) - 3.6 compared with 2.9 (U= 132, 
p<. 02) 
Being happy with script, coping with life, and reporting improved life quality (all 5 
point scales) were all highly positively inter-correlated, as might be expected - 
meaning that when a significant effect for one is observed, it tends to be observed for 
the other two (eg. effects of script type). None of the three psychological variables 
were correlated with age. 
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4.4 Illicit Drug use (and nicotine/alcohol) 
The sample reportedly spent an average of just over 2 hours per day on drug related 
activities (illicit and legal activities), and spent an average of £683 per month on illicit 
drugs (about £22.50 per day). The consumption levels (frequencies and costs) for each 
main drug consumed are shown in Table 4.4 below: 
Table 4.4: Drug consumption: past-month use, frequency of use, weekly amounts, 
and monthly spending 
Monthly 
Past-month Frequency of use Weekly amounts spending 
Use Daily Weekly LTW Mean (SD) Mean (SD) [n] 
Alcohol 35% 16% 9% 1% 40 (35) 
Nicotine 82% 77% 00 124 (52) 
Cannabis 59% 40% 4% 1% 12.2 (8) 
Heroin 61% 31% 13% 3% 4.1 (3.1) £638 (688) [76] 
Diamorphine 9% 4% 2% 1% 1183 (1066) £184 (285) [9] 
Methadone 11% 6% 2% 1% 347 (337) £91 (133) [12] 
Amphetamine 5% 0 2% 0 2.2 (1.6) £100 (49) [5] 
Cocaine 17% 1% 8% 3% 3.6 (4.1) £268 (283) [161 
1+ illicit drugs 70% . All drugs: £683 (788) [761 Notes: 
The three figures for frequency of use do not add up to the figure for all past-month use partly because 
some people indicated that they used but did not indicate the frequency 
Amounts: in grams - except: alcohol (standard units), nicotine (number of ciga rettes), and 
pharmaceutical di amorphine and methadone (milligrams) 
Significant effects of script type were found for use of speed, cocaine and cannabis: 
Clients on mixture scripts were significantly more likely to use speed than clients on 
reefers or ampoules. (Chi Sq=3.43, df=1, p<. 03) (8% and 0%) 
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Clients on ampoules were significantly more likely to use cocaine than clients on 
reefers or mixture. (Chi Sq (YC)=5.82, dfl, p<. 02) (32% and 12%) 
Clients on mixture used significantly less cannabis than those whose scripts include 
reefers or ampoules. (t=2.2, df 68, p<. 03) (9.2g compared to 15.9g) 
Ninety three (70%) clients reported using illicit drugs as well as the prescription they 
received from the clinic, half (48%) injected the drugs. 68% of these injected on at 
least a daily basis, with heroin being the most common drug for 54%. Fifty one 
percent cited a dealer as their main source, and 33% cited a combination of other 
users/dealers as the source for these illicit drugs, 16% reported using wages to pay for 
them, and 84% reported using social security benefits. 
4.4.1 Total monthly drug cost. 
Table 4.4: shows the average monthly spending on each of the five main illicit drugs 
(excluding cannabis). The largest amount is spent on heroin, with one third of clients 
using daily, and with an overall average consumption of just over 4g per week, 
followed by cocaine and diamorphine. The least amount spent was for methadone and 
amphetamine. 
Clients whose scripts include mixture spend significantly less on drugs than clients 
whose scripts include ampoules or reefers. (t=2.04, df--47.9, p<. 05) 
Mixture = mean of £493, Amps/Reefers = mean of £875 
There is a significant positive correlation between age and total monthly drug costs (r 
= +. 34, p< . 
003, n= 75) - further analyses reveal this overall effect to be based 
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mainly on a correlation between age and monthly spending on heroin (but not other 
drugs). Age is also correlated with monthly amount of illicit heroin used in grams (but 
not amounts of other drugs consumed). In short this shows that heroin users tend to 
buy and use more heroin, but not other drugs, as they get older (as their habit grows). 
Clients whose scripts included injectable drugs (ampoules) allocate significantly less 
time to drug-taking activities compared with other clients (mainly on mixture and/or 
reefers) - 1.4 hours compared with 2.3 hours (U = 104, p<. 005) 
4.5 Criminal activities. 
Clients were asked to indicate how often they had engaged in a range of criminal 
activities during the last month; ranging from every day to not at all within the last 
month. 
The table below gives a breakdown of the self-reported types of criminal activities 
undertaken by the clients along with their frequency. In total 1459 separate crimes 
were reported in the month prior to interview, ranging from shoplifting to burglary, 
with 20% of clients reporting criminal activity on a daily basis and 75% reporting 
criminal activity at least once every week. 
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Table 4.5: Reported Frequency (%) & Types of Criminal activity during the 
month prior to interview. 
Number (%) of clients committing crime 
daily 3-4 per 1-2 per 11 1 per 1 per Total incidence 
week week fortnight month per month 
Burglary _0 1(22) 5 (50) 6 (20) 5 (8) 58(4) 
Shoplifting 7 (39) 14(37) 20 (22) 3(l) 2 (1) 534(37) 
...... .... Dealing [script] _0 ýi 2(39) 5(42) 5(14) 11 4 (5) 72 (5) I 
Dealing 13 (77) 5 (15) 6 (7) 0 ý{ 3 (1) 473 (32) 
Prostitution 00 ý( 4 (89) 1 7) 1 (4) 27 (2) 
Theft from 2(43) '3 (33) 4 (19) 2 (3) 3 (2) 129(9) 
family 
Other crime/s 5 (84) 1 (9) 2 (7) 0 (( 0( 166 (11) 
. ...... _. f re Total re R'o 
crim. activity 27 26 46 17 18 
Total incidence 
of crim. activity 1459 (100) 
The two most common types of criminal behaviour reported are shoplifting and drug 
dealing, making up 37% and 32% of the total number of incidents respectively. 
Ninety eight percent of those who report shoplifting do so at least once every week, 
with the vast majority (76%) committing offences almost every day. Ninety two 
percent of those who report drug dealing consist of clients who report dealing every 
day (77%). `Other' crimes were either theft from or of a motor vehicle. (see Table 4.5 
above) 
77 
4.5.1 Drug Dealing. 
Of those clients who reported drug dealing, those on mixture dealt every day, while 
drug dealers on other scripts were more likely to be dealing on a non-daily basis. 
However, looking at the total sample, only 10% of those on mixture reported dealing, 
as compared to 16% of those receiving ampoules and 19% of those receiving reefers. 
(see Table 4.6) 
Table 4.6: Number (%) of drug dealing clients who sold drugs on a daily, near- 
daily or weekly basis, broken down by four forms of script 
%of 
Daily 3-4/week 1-2/week Total total gp. 
Ampoules 1 (20) 1 (20) 3 (60) 5 (21) 16% 
Mixture 7(100) 0 0 7(29) 10% 
Reefers 4 (45) 2 (22) 3 (33) 9 (37) 19% 
Combined 1 (33) 2(67) 0 3 (13) 
TOTAL 13(54) 5(21) 6(25) 24(100) 
As mentioned in the introduction, a major concern raised by many in the discussions 
surrounding the costs/benefits of flexible prescribing is black-market leakage, and the 
potentially lucrative märket for ampoules and to a lesser extent reefers. The following 
table summarises reported script dealing across the four groups; 
Table 4.7: Numbers (%) of script-leaking clients who passed on their script on a 
weekly, fortn ightly and monthly basis, broken down by four forms of script 
group 
3-4/week 1-2/week 1/fortnight 1/month Total % 
Ampules 0 1 (50) 0 1 (50) 2 (12) 6% 
Mixture 1 (14) 2 (29) 3 (43) 1 (14) 7 (44)10% 
Reefers 1 (25) 2 (50) 1 (25) 0 4(25) 8% 
Combined 0 0 1 (33) 2 (67) 3 (19) 
TOTAL 2 (13) 5(31) 5(31) 4(25) 16(100) 
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4.5.2 Script-leaking. 
In terms of script leaking (dealing part or all of their own prescription), only 6% of 
those receiving ampoules reported selling/passing on their script, as compared to 8% 
and 10% for those on reefers and mixture respectively. Amongst those who do report 
dealing part/all of their scripts, 44% receive mixture (see Table 4.7) 
4.5.3 Shoplifting. 
Reported shoplifting figures were very similar for those receiving ampoules and those 
receiving mixture; 29% for the ampoules group and 27% for the mixture group. Those 
receiving reefers reported much lower levels, with 15% of the group reporting that 
they had shoplifted, however of these, 29% reported shoplifting on a daily basis. 
Whereas shoplifters in the other three groups were more likely to be doing it on a 
weekly basis. (see Table 4.8) 
Table 4.8: Number (%) of shoplifting clients who stole from shops on a daily, near- 
daily or weekly basis, broken down by four forms of script I% of 
Daily 3-4/week 1-2/week Total total gp. 
Ampoules 1 (11) 3 (33) 5 (56) 9 (21) 29% 
Mixture 3 (15) 9 (45) 8 (40) 20 (48) 27% 
Reefers 2 (29) 2 (29) 3 (42) 7 (17) 15% 
Combined 1 (20) 0 4 (80) 5 (13) 
TOTAL 7(17) 14(34) 20(49) 4](100) 
Significant effects of script type were found only for shoplifting and prostitution. 
Clients on reefers are significantly less likely to shoplift compared with other clients 
(mainly on mixture or ampoules), 23% compared with 41%. 
(Chi Sq= 3.75, df= 1, p<. 05) 
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4.5.4 Prostitution 
Clients on mixture were significantly more likely to do prostitution than other clients 
(mainly on ampoules or reefers), 8% compared with 0%. 
(Chi Sq= 3.43, df= 1, p<. 03) 
As stated in section 4.2 there are clear gender patterns which almost certainly account 
for these two significant effects. These effects must be viewed alongside the gender of 
those clients receiving mixture scripts, who are 33% female, as compared to an 
overall sample percentage of 24% female. Only 4% of those clients receiving reefers 
are female. It is widely accepted that the two crimes most frequently carried out by 
female drug users are shoplifting and prostitution. It therefore seems fair to conclude 
that these two effects are the product of a gender bias in the make up of the script 
group, rather than a product of the nature of the script itself. 
4.6 Crime and Drug Use 
(As expected) There were several significant effects of `past month crime' (either did 
no crime in the past month, or did) on overall drug use and overall drug buying: 
72% of past month drug buyers had done 1+ crimes 
35% of past month non-buyers of drugs had done 1+ crimes 
Chi (YC)=13.73, df=1, p<. 001 
Similarly: 
76% of past month drug users had done 1+ crimes 
33% of past month non-users had done 1+ crimes 
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Chi (YC)=21.26, df--1, p<. 001 
The latter effect seems to be based largely on two types of drug use: heroin 
and cocaine, i. e. 
75% of past month heroin users had done 1+ crimes 
44% of past month non-users of heroin had done 1+ crimes 
Chi(YC)=11.84, df=1, p<. 001 
100% of past month cocaine users had done 1+ crimes 
56% of past month non-users of cocaine had done 1+ crimes 
Chi(YC)=13.54, df1, p<. 001 
(Raw data/frequencies for Chi Square Calculations can be found in the appendices, 
p137. ) 
/ 
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Chapter Five - DISCUSSION 
5.1 Overview 
Summary of Key Findings 
Key findings can be sub-divided into categories according to the initial aims of the 
study, which were; 
`... to assess several inter-linked questions within a harm reduction framework. Three 
key areas and their association with heroin substitution prescribing will be addressed; 
levels of criminal activity, levels of illicit drug use, and a range of client held 
perceptions and attributions regarding coping/quality of life etc. ' 
Each of the three areas were examined according to the type of script an individual 
client received, with the two primary script variables being form (whether the script 
was injectable, in mixture form, or in the form of smokable reefers), and type of drug 
(whether the script was for methadone or diamorphine/heroin). Significant effects are 
summarised in Table 5.1 below: 
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Table 5.1: Summary of significant effects (and p. values) 
Drug use Crime Perceptions & 
Attributions 
- Use significantly - Significantly more - Significantly less 
Prescription includes more speed than those likely to do prostitution happy with 
mixture on reefers/amps than those on prescription than those 
(p<. 03) reefers/amps (p<. 03) on reefers/amps 
- Use significantly less (p<. 002) 
cannabis than those on 
reefers/amps (p<. 03) 
- Spend significantly 
less money on drugs 
than those on 
reefers/am s (<. 05) 
- Sign if icantly more - Significantly more 
Prescription includes likely to use cocaine able to cope with life 
ampoules than those on than those on 
reefers/mixture (p<. 02) reefers/mixture (p<. 02) 
- Significantly more 
improved quality of life 
than those on 
reefers/mixture (p<. 02) 
- Significantly less time 
taken up with drug 
taking activities than 
those on 
reefers/mixture 
(<. 005) 
- Significantly less 
Prescription includes likely to do shoplifting 
reefers than those on 
mixture/amps (p<. 05) 
Methadone mixture - Significantly less 
prescription happy with 
prescription than those 
on reefers (p<. 02) 
5.1.1 Key findings in relation to criminal activity 
In relation to criminal activity, two significant effects were found, for shoplifting and 
for prostitution. Clients receiving reefers were significantly less likely to shoplift 
compared with those on other scripts. Clients receiving mixture based scripts were 
significantly more likely to engage in prostitution than those on other scripts. These 
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effects must however be viewed alongside the gender of those clients receiving 
mixture scripts, who are 33% female, as compared to an overall sample percentage of 
24% female. Only 4% of those clients receiving reefers are female. It is widely 
accepted that the two crimes most frequently carried out by female drug users are 
shoplifting and prostitution. It therefore seems fair to conclude that these two effects 
are the product of a gender bias in the make up of the script group, rather than a 
product of the nature of the script itself. 
Seventy five percent of the sample reported committing a least one crime every week; 
in the main this was either shoplifting or drug dealing. There were a total of 1459 
crimes reported for the month prior to interview, which represented an average of 11 
crimes per client. There were some interesting findings in relation to three specific 
crimes; drug dealing, script leaking, and frequency of shoplifting. Of those clients 
who reported drug dealing, those on mixture dealt every day. However, looking at the 
total cohort, only 10% of those on mixture reported dealing, as compared to 16% of 
those receiving ampoules and 19% of those receiving reefers. 
As regards script leaking (dealing part or all of their own prescription), only 6% of 
those receiving ampoules reported selling/passing on their script, as compared to 8% 
and 10% for those on reefers and mixture respectively. Amongst those who do report 
dealing part/all of their scripts, 44% receive mixture. Reported shoplifting figures 
were very similar for those receiving ampoules and those receiving mixture; 29% for 
the ampoules group and 27% for the mixture group. Those receiving reefers reported 
much lower levels, with 15% of the group reporting that they had shoplifted, however 
of these, 29% reported shoplifting on a daily basis. 
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5.1.2 Key findings in relation to illicit drug use (and alcohol/nicotine) 
There was a significant positive correlation between the age of a client and their 
monthly level of spending on illicit drugs, this was primarily based on a correlation 
between age and spending on heroin in particular. On average each client in the 
sample spent over £680 (£22.50/day) per month on illicit drugs. However, one of the 
more interesting findings was that clients whose scripts include mixture spend 
significantly less on drugs than clients whose scripts include ampoules or reefers. 
An average of £638 per month was spent on 4.1 grams of heroin per client. Cannabis 
was the second most popular drug, with 59% of the sample consuming an average of 
12.2 grams per week. 
Clients reported spending, again on average, just over 2 hours per day on drug related 
activities. The exceptions to this were clients whose script included injectable drugs 
(ampoules) who spent significantly less time on drug related activities compared with 
other clients. Those on ampoules spent an average of 1.4 hours per day as compared 
to 2.3 hours for those on mainly mixture and/or reefers. 
There were three significant effects of script type on the use of specific drugs, speed, 
cocaine and cannabis; Clients on mixture scripts were significantly more likely to use 
speed than clients on reefers or ampoules, Clients on ampoules were significantly 
more likely to use cocaine than clients on reefers or mixture, and Clients on mixture 
used significantly less cannabis than those whose scripts include reefers or ampoules. 
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More than two thirds (70%)of the sample reported using illicit drugs along with their 
script, and half of these (48%) injected illicit drugs. Heroin was the most commonly 
used illicit drug (61 % of clients reported using it in the past month), followed by 
benzodiazepines (17%), cocaine (17%) and methadone (11%). The vast majority 
(87%) acquired these illicit drugs from either a dealer or other users, and most (84%) 
reported using social security benefits to pay (at least in part) for them. 
Seventy seven percent of the sample smoked daily, with an average of 18 cigarettes 
per day. Only one third of the sample reported consuming alcohol in the past month, 
however those who did consume alcohol reported an average consumption of 40 units 
per week -a far higher figure than the national average (in 2002 the mean weekly 
consumption for men was 17 units and 8 units for women, ONS 2004). 
5.1.3 Key findings in relation to client perceptions and attributions. 
In terms of client perceptions and attributions, four significant effects were found; two 
related to satisfaction with their script, and one each related to perceived self-efficacy 
and quality of life. 
Focusing on the form of the script (ie amps/mixture/reefers), those clients whose 
scripts included mixture were significantly less happy with their script compared with 
other clients. (ratings of 2.7 and 3.9 respectively) Focusing on specific drug+form 
combinations, those clients on methadone mixture were significantly less happy with 
their scripts compared with clients on heroin reefers. (ratings of 2.4 and 3.6 
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respectively). Its clear that clients preferred heroin to methadone, and injectables and 
smokables to mixture. 
The rating scale ran from 1 (very unhappy) to 5 (very happy), with 3 representing 
neutral. The mean for the total sample was 2.95, the mode was 4.0. 
The other two significant effects observed both focused on those receiving injectable 
drugs as part or all of their script; these clients perceived themselves as significantly 
more able to cope with life compared with other clients (on mainly mixture and/or 
reefers), and they also perceived their quality of life, compared with one month ago, 
as significantly more improved compared with other clients. (this may be because 
injectors have more room for improvement? ) 
5.1.4 Key findings in relation to Crime and Drug Use in combination 
As expected, there were significant effects of past month crime (either committed a 
crime in the past month or didn't) on overall drug buying, and overall drug use 
(although this is based largely on specifically heroin and cocaine use). Those who had 
bought drugs had committed significantly more crime than those who hadn't, and 
those who had used illicit drugs in the past month had committed significantly more 
crime than those who had not used illicit drugs. Focusing on heroin and cocaine; 75% 
of heroin users had committed crime (compared to 44% of non heroin users), and 
100% of cocaine users had committed crime (compared to 56% of non cocaine users). 
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5.2 Interpretation of findings. 
In terms of their relevance to the material/studies cited in the Introduction, the 
findings of this study will address each of the stated concerns regarding the 
advantages and disadvantages of prescribing heroin in the treatment of opioid 
dependency. One way of summarising these advantages and disadvantages is as 
follows: 
5.2.1 Two dimensions of drug taking consequences 
The findings of this study will be interpreted in terms of Newcombe's two- 
dimensional scheme, which produces nine categories of drug taking consequences 
from the three-valued dimensions of type and level. (Newcombe 1991). The 
development and implementation of a conceptual framework allows practitioners and 
policy makers to measure the relative effectiveness of specific harm reduction 
initiatives. Harms and benefits can be organised according to many schemes, 
depending on the objectives of the classifier and tolerance for complexity. In this two- 
dimensional scheme the `type' dimension has three levels: health (including physical 
and mental health), social (including public order/disorder, social integration etc) and 
economic (financial factors). The `level' dimension refers to: individual (the drug 
user), community (including family, friends, neighbours), and societal (criminal 
justice/health services, overriding culture). The original scheme, including examples 
of selected consequences is shown in table 5.2. 
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Table 5.2: Two-dimensional scheme; Model of drug-related consequences 
(Newcombe 1991) 
Type of drug related harm 
Level Health Social Economic 
Individual eg. infection due to 
poor injecting 
technique 
Community eg stigmatisation of 
the relatives of a known 
problem drug user 
Societal eg the cost of drug 
related law 
enforcement 
As stated in the Introduction, in terms of prescribing heroin as an effective 
substitution treatment, it appears that some medical practitioners and government 
policy makers are at odds in terms priorities; the medics prioritising the need of the 
individual to be drug free/healthy, and the policy makers prioritising the needs of the 
wider community in terms of the reduction of crime/other costs. An effective 
treatment strategy clearly needs the support of both groups, and will therefore have to 
address clinical needs and societal needs. In terms of the two-dimensional scheme 
economic needs will also have to be addressed. 
In terms of this two dimensional scheme, the relative advantages and disadvantages 
associated with prescribing heroin, can be mapped out as per the tables below: 
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Table 5.3: Model of drug-related consequences: Positive features of prescribing 
heroin (adapted from Newcombe 1991) 
Type of drug related harm 
Level 
Individual 
Community 
Societal 
Health 
I 
'clean' unadulterated 
drugs, measured doses 
4 
more users attracted 
Into treatment + off 
the streets 
7 
reduced amounts of 
street drugs around 
due to less demand 
Social 
2 
stabilised - possible 
to work/meaningfully 
contribute to society 
5 
reduces the need for 
pyramid' selling - 
reducing demand 
8 
reduced demand on 
social services/crisis 
intervention services 
Economic 
3 
no need to steal 
etc to fund habit 
6 
reduction in 
crime will see 
insurance drop 
9 
reduced costs 
of drug related 
law enforcement 
(numbers will be used for reference in the text below) 
Table 5.4: Model of drug-related consequences: Negative features of prescribing 
heroin (adapted from Newcombe 1991) 
Type of drug related harm 
Level 
Individual 
Community 
Health 
10 
prolongs the drug 
using career 
13 
more pure heroin 
around, T risk of 
diversion 
Social 
11 
potential fort in very 
specific heroin related 
problems eg pregnancy 
14 
heroin use may be 
perceived as more 
normal/mainstream 
Economic 
12 
no incentive to 
work, pay tax 
contribute etc 
Societal 
16 
T presc. of h at the 
expense of other 
drugs/patients 
15 
no illegal income so 
more reliant on 
benefits if not in work 
17 18 
increased need for control increased costs 
and lain enforcement to to pay for health 
police the programme & legal services 
(numbers will be used for reference in the text below) 
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5.2.2 Findings in relation to previous research and theoretical issues. 
Findings can be grouped into the following broad categories (and will be discussed in 
relation to previous work and the dimensions illustrated in the previous tables): 
Prescription factors - including the form of the prescription, the content (including 
dose levels) of the prescription, and criteria for prescribing heroin. 
Client factors - including perceptions and attributions, the risk of prolonging 
addiction/injecting, health implications, retention figures, and measures of self- 
efficacy 
Socio-Economic factors - including the impact on crime and criminal activity, cost 
implications and the issue of dispersion. (Dispersion crosses all three groups of factors 
if issues of supervised consumption and/or daily `pick ups' are to be considered in 
response to concerns about leakage and the creation of a new group of clients). 
5.2.2.1 Prescription factors 
The finding that those prescribed ampoules spent significantly less time per day on 
drug related activities (which included committing crime) than those on other scripts, 
concurs with the findings of McCusker et al (1996). This suggests support for the 
assertion (boxes 2+3 above) that in terms of reducing harm in the Social/Individual, 
and Economic/Individual categories, stabilising clients (on injectables in this case) 
allows opportunities to spend time more productively and to move away from 
criminal activity. The findings of the McCusker study are considered particularly 
relevant to the present study for two reasons: the study was also based in the North 
West of England (Manchester), with geographical, political and prescribing 
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similarities, and it was conducted during approximately the same time period 
(1995/6) 
In terms of the impact of prescription factors, the randomised control of treatment 
regimes is possibly the biggest single influence in terms of securing empirical 
evidence to support/challenge the effectiveness of prescribing heroin. Clients in the 
current study were already registered at the clinics, receiving treatment based on 
clinical prescribing guidelines and individual drug taking histories. It is difficult to 
imagine another UK trial that would secure ethical approval for a randomised 
allocation of clients, and as such, Hartnoll at el's (1980) findings will continue to 
attract attention as the only UK study of its kind. 
The other major prescription factor, and one that was frequently mentioned in all of 
the previous key studies, was dose, and in particular the heroin dose. The fact that the 
heroin dose was relatively small compared to the methadone dose available was cited 
as a major confounding variable in both the Metribian et al (2001) and Hartnoll et al 
(1980) studies. The Swiss and Dutch studies did not restrict dose, but they did enforce 
supervised consumption. (risk of dispersion was cited as one of the main reasons why 
Metribian el al (2001) and Hartnoll at al (1980) did cap the heroin doses) In the 
current study, the mean ampoule dose was 155mg, mixture dose was 64mg, and the 
mean reefer dose was 360mg (reefers were dispensed in either 60mg or 100mg 
amounts per cigarette, and larger amounts were prescribed to account for poor 
inhalation and/or sidestream loss). Overall, both in this study and in the other three 
UK based studies, prescribed doses of heroin were much smaller than those prescribed 
in either the Swiss or the Dutch trials. (see Table 5.5) 
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Table 5.5: Daily doses of heroin - UK, Swiss & Dutch trials. 
UK Switzerland 3 Netherlands 4 
Regulation No upper limit None 1000mg daily and 
or guideline. no single dose 
greater than 400mg 
In practice Range 5-1,500mg i 500mg for Mean 549mg for 
injectable heroin injectable heroin 
Mean 175mg 2 1,000-1,850mg for Mean 539-547mg 
smokable heroin for smokable heroin 
notes: 
1. Metribian et al (2002), 2. Strang and Sheridan (1997), 3. Uch tenhagen et al (1999), 
4. van den Brink et al (2002) 
source: Stimpson and Metribian (2003) 
In terms of dose, the capped levels of heroin in each of the three main UK trials 
compromises any conclusions regarding the relative effectiveness of heroin versus 
methadone in terms of any illicit drug use associated with each script. The current 
study recorded doses (mean ampoule dose 155mg, mixture dose 64mg), which are 
approximately in line with current recommendations regarding conversions between 
oral methadone and injectable heroin doses. The NTA (2004) recommends that a daily 
dose of injected heroin of between 141-180mg converts to between 50-60mg of oral 
methadone. Parry (1992) reviewed available evidence and concluded that an optimal 
daily dose regime of heroin is generally between 300-400mg, and he further argues 
that any attempts at heroin maintenance with daily doses of no more than 100mg will 
inevitably lead to `topping up'. 
Establishing clear criteria for identifying which clients have a clinical need for heroin 
is a crucial aspect of any treatment programme proposing to prescribe injectable 
(and/or smokable) opiates. If these criteria are explicit and measurable they will help 
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clinicians identify those clients for whom heroin is the best option, and go some way 
to reducing dispersion by ensuring the correct client gets the correct script. In the 
current study, those receiving injectable/smokable scripts had to comply with the 
prescribing guidelines issued by the Department of Health, those being; confirmed 
(using urine samples) physical dependency on heroin and/or, regularly using heroin 
intravenously, and/or had a minimum of six months regular non intravenous use. The 
client must also show that they are motivated to change at least some aspects of their 
drug use. Other considerations included a comprehensive assessment (history, urine 
toxicology, drug diary) and a doctor/team decision that the client was willing to 
comply with the requirements of the prescription regime. (DoH 1991) 
The admission criteria for the Swiss and Dutch trials were generally stricter than those 
above. For example, the Swiss trial required clients to have had a heroin dependency 
for a minimum of two years, to have had a negative outcome on at least two previous 
treatments, and to have documented health and social deficits as a direct consequence 
of heroin dependence. The Swiss trial was particularly interesting as it continues to be 
the only one which addresses the concern that clients might somehow `choose' to fail 
in methadone treatment to secure a place on a heroin programme. Of the 24 clients 
who missed out on the initial chance to receive a heroin script (randomly allocated), 
only nine opted to make the switch from methadone to heroin when offered the 
chance six months later. (In spite of the fact that all clients had wanted heroin at the 
onset of the trial) (this also ties in with box 10 above). 
In terms of identifying those clients best suited to heroin substitution treatment, 
Hartnoll et al (1980) stated that theoretically it should be possible to determine who 
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will benefit from which type of treatment. However they go on to suggest that 
individual clients can change in their capacity to respond to clinical intervention, and 
once an injectable prescription is initiated, it can then prove difficult for the clinician 
to alter. Hartnoll et al also suggest that the rapid sharing of information which exists 
in any sub culture inevitably results in the treatment offered to one client raising the 
expectations of others. 
5.2.2.2 Client factors 
Ashton and Witton (2003) raised the question that the attraction of prescribing 
diamorphine may at the same time be one of its major drawbacks. The opportunity to 
receive safe, high quality and free diamorphine may prove to be a significantly 
effective motivator to `fail' in methadone treatment. In addition, it could also be 
argued that once stabilised on their drug of choice, the prescription of diamorphine 
could in fact prolong an addict's period of addiction. 
The issue of retention rates was not explicitly addressed in the current study, as 
external factors prevented a longitudinal follow up. However, if the 
perception/attribution factor of how happy clients report being on particular scripts is 
taken as a possible indicator of how likely it is that clients would remain in treatment, 
then the findings that: firstly, those clients whose scripts included mixture were 
significantly less happy with their script compared with other clients; and secondly, 
that those clients on methadone mixture were significantly less happy with their 
scripts compared with clients on heroin reefers, would both support the findings of 
Hartnoll et al (1980) who found 76% of those receiving diamorphine were still in 
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treatment 12 months later, compared to 26% receiving oral methadone. Conversely, 
the Dutch study found that 86% those clients receiving methadone completed the 12 
months of treatment as compared to 70% of those prescribed injectable heroin. (van 
den Brink et a! 2002). One possible explanation for this could be the strict demands 
placed on those clients attending the heroin treatment regime, many of whom were 
forced to leave for disciplinary rule-breaking reasons. Others may have voluntarily 
decided to opt into the methadone programme once stabilised on heroin, to eliminate 
the need for daily pick ups and supervised consumption etc. (this factor may in part 
relate to box 10 above, and may hold the key to achieving a balance between treating 
the clients addiction and prolonging it). 
One of the specific health factors, which may be associated with increased harm 
following heroin prescribing, is pregnancy. This was not investigated as part of the 
current study however it does warrant some discussion as it featured in one of the key 
previous trials. Pregnant or breast feeding women were excluded from the Dutch and 
UK trials. There were 12 pregnancies in the Swiss trials between 1994 and 1996, 
these resulted in eight live births, three terminations, and one spontaneous abortion 
during heroin withdrawal. These results were similar to those for women receiving 
methadone maintenance treatment. (Bammer et al 2003) It would seem fair to suggest 
that the advantages associated with retaining the pregnant client in heroin treatment in 
terms of additional health/welfare support, may out weigh the negative effects 
associated with experiencing pregnancy whilst using heroin illegally, outside of the 
treatment system. However, in 2004 the National Treatment Agency issued a dosing 
guidance paper for pilot sites planning to offer IOT (Injectable Opiate Treatment) and 
concluded that due to a lack of adequate research regarding IOT, (and in recognition 
of the relatively large amount of evidence regarding oral methadone in pregnancy) 
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"IOT cannot be routinely recommended in pregnancy" (NTA 2004) 
(box 11, p91) 
Dr John Marks, the consultant psychiatrist at the two community drug teams at the 
centre of this study summed up the findings of longitudinal research into heroin use, 
that the average `career' of a heroin user was approximately 10 years, after which 
time the user would either stop, switch to methadone, be residing in prison or be dead. 
(Marks 1991). He suggested that one of the goals of treatment was to minimise the 
harm experienced by the user during this 10 year period, empowering the individual 
and keeping them healthy. This belief underpinned his faith in the merits of flexible 
prescribing, including injectable and smokable heroin. In the current study, clients 
whose scripts included injectable drugs perceived themselves as significantly more 
able to cope with life compared with other clients, and those clients whose scripts 
included injectable drugs perceived their quality of life, compared with one month 
ago, as significantly more improved compared with other clients. The findings of the 
Swiss study also showed positive changes for those prescribed heroin; 
accommodation situations had improved and employment rates had doubled. 
(Uchtenhagen et al 1999) 
5.2.2.3 Socio-Economic factors 
Criminal activity will continue to play a central role in any discussion about drug 
treatment, heroin based or otherwise. Its clear from this study that criminal activity 
was present across all script groups/combinations, albeit in slightly differing amounts. 
With no baseline measure of criminal activity prior to treatment it is not possible to 
assess the impact of script on subsequent criminal behaviour for this sample. Those 
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studies, which were able to establish baseline measures of criminal behaviour all, 
found that crime was reduced but not eliminated. The Dutch study found that only 
half of the clients receiving heroin were involved in crime after 12 months in 
treatment, while crime amongst the control group remained high. (van den Brink et al 
2002). Hartnoll et al (1980) and Metribian et al (1998) both found that crime was 
reduced but not eliminated. 
In terms of dealing part/all of their script, those receiving essentially mixture form 
based prescriptions reported very similar (but still relatively low compared to 
frequencies of other types reported) levels of crime to those receiving reefer-based 
scripts. In contrast those receiving ampoules reported low levels of script dealing - 
this has clear implications for concerns raised about dispersion and supervised 
consumption. 
The costs of prescribing heroin are often significantly increased, as they were in the 
Swiss and Dutch trials, by costs associated with supervised consumption designed to 
monitor dosing levels, advise on injecting techniques, and prevent dispersion. 
As a result of supervised consumption, dispersion was not an issue in the Swiss and 
Dutch trials, however in the UK heroin is/was prescribed like any other drug; for 
consumption at home. The practicalities of turning criteria established for a trial into 
generic treatment practice require a significant amount of planning, not least in terms 
of establishing a network of accessible locations at which clients could inject. One 
possible answer, trialed during the Metribian et al (2001) study, would be to require 
clients to return used ampoules before receiving new ones. (box 13, p91. ) (recently the 
use of marker chemicals has also been suggested, they are added to the ampoules and 
clients are randomly tested for them). 
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Advocates on both sides of the prescribing heroin debate to support their case cite cost 
implications. (boxes 9,15+18) Stimpson and Metribian (2003) estimated that it costs 
between £7,717-£9,691 per addict per year to prescribe (a supervised) injectable 
heroin script, compared to £2,800 for a methadone prescription (excluding supervised 
consumption). It is true to say that the differences in cost are often related to the 
manufacturing process rather than the pharmaceutical process, along with the nature 
of the script delivery. (eg. frequency of `pick ups' influences pharmacy related 
charges). At the time of this study the relevant prescription costs per year were £100- 
£200 for oral methadone, £300-£600 for reefers, and £1000-£2000 for injectable 
opiates. (Marks et al 1991) 
Strang and Farrell (1992) stated that: 
"On any day nearly a quarter of a million clients receive oral methadone 
worldwide, compared with probably fewer than 1000 who receive injectable 
methadone, morphine or heroin" (p182) 
It is clear that factors other than prescription cost must be established if those who 
advocate prescribing heroin are to convince the policy makers of its financial merits. 
In the case of the Swiss study, the calculated comparison of the treatment costs with 
the economic benefits, showed that there was a total benefit per patient per day of 
$26.00. (Treatment costs, including drug, personnel, location, hours of operation etc. 
were on average $30.00 per day. The economic benefit, including reduced cost of 
criminal investigations and imprisonments, were estimated at $56.00 per day) 
(Brehmer & Iten 2001) 
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5.3 Critique of methodological approach 
Ashton and Witton (2003) highlighted the fact that "despite its unique history, British 
evidence on diamorphine's value is thin... Worldwide there are just five directly 
relevant studies". In designing and implementing this study, it became clear as to why 
there have been so few pieces of empirical work in the area of heroin substitution 
treatment. 
5.3.1 Complexity of design 
This study did not include a pre treatment measure, and was in effect a `snapshot' of 
clients in-treatment behaviour during the month prior to interview. As such, no 
baseline measures were taken, for example regarding drug use and criminal activity, 
with which to then compare behaviour whilst receiving a particular 
script/combination. Baseline factors are also relevant when looking at the time clients 
had been registered at the clinic. With a range of between 1 month and 21 years (mean 
three years) its clear that; i) baseline criteria figurers for 20 years ago, the mid 80's, 
when treatment practices had different areas of emphasis, would be potentially very 
unlike those relevant to clients presenting for treatment today. (Indeed, issues relevant 
at the time of this study, 1995-97, are now moving `full circle' with what was a rather 
unusual prescribing practice in the mid to late 90's now being experimented with by 
senior healthcare policy makers and government ministers). 
In a laboratory setting, the ability to control extraneous variables whilst randomly 
allocating matched participants to experimental and control groups, is clearly one of 
the most valid methods of evaluating the effectiveness of particular 
101 
interventions/treatments. However, when working with problem drugs users this is 
seldom possible for a variety of practical and ethical reasons. A random allocation of 
clients (who meet certain criteria for inclusion) as they present at CDT's would of 
course enable researchers to attribute resulting differences to prescribing regimes 
rather than client characteristics. The practicalities of this are not quite as 
straightforward. In the present study, the consultant psychiatrist and his team, with 
prescription form and drug being decided upon in response to a range of clinical and 
health related measures, had already assessed clients. It may well be the case that with 
the recent government statements regarding a possible expansion of the heroin 
prescribing `base', future work may well be able to adopt a random allocation policy, 
possibly with the use of a placebo. The ethical considerations will remain, particularly 
if results go on to show that those receiving the control/placebo continued to commit 
crime, do harm etc. 
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5.3.2 Representativeness of sample. 
In the current study, the sample was essentially representative of the population from 
which they were taken (total number of clients registered at the 2 clinics) in terms of 
age and gender. However, as cited in the Introduction, prescribing practices vary 
nationally from region to region, (dependant on a number of factors including the 
clinical judgement and practices of the consultant psychiatrist), and it is not therefore 
possible to draw direct comparisons with clients registered at clinics elsewhere. The 
fact that the government now seems keen to initiate national treatment policies across 
the country, offering similar services regardless of location, may well address this. 
The various national treatment agencies, drug data bases and government papers are 
all contributing to a more coherent nationwide treatment programme, which should 
help researchers conduct studies, the findings of which will be more representative of 
the problem drug using population as a whole. 
In terms of the five key previous studies, Stimpson and Metribian (2003) suggested it 
was unclear as to how far the results were generalisable given the different treatment 
contexts within which each was carried out. They conclude: 
"comparing the UK, Swiss and Dutch evidence shows up differences in the 
way in which heroin treatment is delivered. The question `does prescribing 
heroin work? ' has to consider whether it works when it is delivered in a 
particular manner, in a particular treatment modality, in a particular treatment 
and country context" (Stimpson & Metribian 2003) 
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5.3.3 Measuring and reporting `effectiveness' 
As reported in Chapter two, it would appear to be the case that medical practitioners 
and government policy makers are at odds in terms priorities; the medics prioritising 
the need of the individual to be drug free, and the policy makers prioritising the needs 
of the wider community in terms of the reduction of crime. A third group, the problem 
drug users, also have a stake in the evaluation and effectiveness of heroin prescribing. 
Any research has cost and other resource implications. This current study benefited 
from the independence associated with academic enquiry, and as such draws 
conclusions, which may legitimately and without favour support and/or refute the 
claims of any one or all of the groups above. It is clear that any piece of research in 
the applied field of drug use will not see positive outcomes in all areas. The current 
study attempted to address issues relevant to the three key groups, whilst at the same 
time offering conclusions in a non-hierarchical manner. 
When reporting findings it is important to remember that they may well offer 
contradictory support depending on the focus of the reader. Emphasis may well be 
placed on free, clean, unadulterated drugs and psychological well-being by the 
problem drug users, on HIV risk behaviour, illicit drug use and general health levels 
by the medical practitioners, and on levels of crime and risk of dispersion, by 
government policy makers. 
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5.4 Implications for prescribing policy and practice 
5.4.1 Government policy for heroin prescribing 
In May 2003, the then Home Secretary, David Blunkett, confirmed that guidelines 
were to be issued to GP's regarding the prescribing of injectable heroin to `hard-core' 
problem drug users in an attempt to curb their criminal behaviour and manage their 
addiction. Blunket stated: 
"we need radical thinking about how we engage them in treatment. Prescribing 
heroin is all about what is right for the individual. It is about making it 
available to all those with a clinical need" (Travis, 2003) 
Also in May 2003, the NTA produced guidelines for practitioners in drug treatment 
services on the potential role of injectable heroin and methadone in the treatment of 
opioid dependency. In these guidelines they made three key recommendations; 
" Optimised oral methadone maintenance should be the maintenance treatment 
for the majority of heroin users 
" Injectable heroin and methadone treatments should be considered only for the 
minority of patients who are genuinely unresponsive to an optimised oral 
maintenance treatment approach 
" Injectable heroin and injectable methadone treatments based on this guidance 
should be seen as a new drug treatment modality requiring the development of 
new integrated care pathways 
In making these recommendations the NTA was keen to emphasise that injectable 
prescribing should be seen very much as the exception rather than the rule. They 
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stressed the importance of eligibility criteria to ensure only appropriate (in terms of 
age, compliance, and previous treatment failings) clients received heroin, and when 
they do receive injectables, that maintaining stability on them is paramount. (NTA 
2003) (To date, NTA documents and policy make no mention of smokables) 
5.4.1.1 Potential problems: GP co-operation 
One of the main problems the government face in their plans to offer increased 
provision for heroin prescribing is from GP's themselves, who's arguments have two 
main areas of focus; liability and funding. 
Some doctors fear that legal action might follow if a patient died as a result of 
overdosing on heroin prescribed by their GP. The secretary of the Royal College of 
General Practioners, Dr Claire Gerada, cautioned against expanding the programme of 
heroin prescribing in primary care settings until the research base in support of this 
was clearer. Dr Gerada also pointed out that heroin is an expensive drug, and that 
once a patient was placed on prescribed heroin it may very likely be for some 
considerable time, possibly for life. As budget holders, GP's would therefore be 
reluctant to take on such a commitment without significant financial support from the 
government in the form of specialist drug treatment contracts. (Travis, 2003) 
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5.4.2 Implications for policy and services 
The biggest implication in terms of policy development seems to centre on the 
growing recognition that it too needs to be flexible. 
In a media statement released on the 15th January 2002, the NTA reiterated its 
commitment to the full range of treatment options, including heroin prescribing, 
which it was suggested could be used as a gateway treatment to encourage `difficult to 
reach' clients into treatment. The NTA stressed the need for a flexible and inclusive 
regard to service development, based on foundations of research and empirical 
evidence: 
"The NTA is interested in what works best for the users, and for the 
community as a whole. We do not have ideological barriers and we will look 
to develop treatment guidance that is based on solid evidence. We will, when 
necessary, commission research to identify best practice" (NTA 2002) 
The NTA are in the middle of a consultation process to set up a trial with around 800 
injectable opiate users being prescribed injectable heroin. As yet the exact details are 
unclear. 
5.4.3 Implications for treatment 
Regardless of the success or otherwise of heroin prescribing, it is clear that it seems 
unlikely to replace oral methadone as the drug of choice for service providers. Its 
widespread introduction would be precluded by a number of factors including expense 
(mainly those associated with imposing safe guards like supervised consumption, 
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medical support etc), and the fact that it has a relatively short acting nature. However, 
even the limited number of studies done to date would suggest that heroin prescribing 
does have an important supporting role as an adjunct to methadone maintenance, 
particularly in terms of treating those clients for whom all other forms of treatment 
have failed. (Bammer et al 1999) 
One of the major concerns regarding the prescribing of heroin is the risk of 
dispersion; this is increasingly held up as one of the most potent and emotive weapons 
in the armoury of those opposed to flexible prescribing. Possible solutions include 
supervised consumption, as in the Swiss and Dutch trials, daily pick-ups, and a system 
of exchange based on returning empty ampoules before receiving new ones (as in the 
Metribian et al. (2001) trial in the late 1990's). Focusing specifically on the UK, 
which has a diverse range of problem drug users who are not all city based or living 
close to clinics, the exchange system may well prove to be the cheapest and least 
intrusive method of preventing dispersion. 
Suggesting a different perspective on the issue of dispersion, John Marks took the 
opinion that restricting heroin to particular people/small numbers is in fact the cause 
of leakage, because a rare and valuable commodity is made, available in a sub culture 
where things are constantly bought and sold. He argues conversely, if heroin was 
really made available to everyone who has a `need', and all clients who wanted it 
were given it, then who would be left to buy the leakege? (Marks 1985) 
In the 2005 update the National Treatment Agency made some significant changes to 
the previous 2002 Models of Care in relation to treatment. (see Table 5.6 below) 
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Table 5.6: NTA Strategies for improving 4 stages of drug treatment 
Stage of treatment 
1 Engagement and retention 
2 Delivery 
3 Maintenance or completion 
4 Reintegration into community 
Effectiveness indicators 
(a) New client numbers & waiting times 
(b) 12-week contact rate 
Care/prescribing plans 
Number of treatment staff 
(a) number stabilised & 
(b) number drug-free 
eg. numbers employed, 
educated, housed, etc. 
Whilst not explicitly referring to heroin prescribing, the broadening of the range of 
available treatments would have clear implications for three of the four stages of 
treatment; 1. Offering injectable/smokable heroin as a potential option may serve to 
attract a more diverse range of clients into treatment, 3. clients may stabilise on heroin 
as their drug of choice, reducing the need to use illicit drugs, and 4. On a stable 
prescription regime, crime free, clients may feel able to stabilise other aspects of their 
lives, similar to those patterns seen in the initial heroin trials in the 1990's. (UK, 
Swiss and Dutch) 
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5.5 Heroin use in the mid 2000's - prevalence/characteristics 
The National Drug Treatment Monitoring System (NDTMS)(run by the NTA), 
produced the following count of problem drug users for 2001-2005: 
Table 5.7: Annual number of problem drug users in treatment in England, 2001- 
2005 
Completed or 
Completed Retained Left treat. OVERALL retained (%) 
2001/02 18,100 (12) 57,400 (39) 70,800 146,300 75,500 (52) 
2002/03 25,000 (15) 55,700 (34) 85,200 165,900 80,700 (49) 
2003/04* 13,000 (10) 77,500 (61) 35,050 125,550 ^ 90,500 (72) 
2004/05 15,800 (10) 104,900 (65) 39,750 160,450 120,700 (75) 
NOTES 
- based on estimation methods employed in 2000/01 to 2002/03 - though the exact comparable figure 
(not reported by NTDTMS) is based on `retained' plus `left treatment' - i. e. 112,900 in 2003/04 
* NDTMS set up in 2000/01, though a new data completion system was introduced in 2003/04, with 
tighter definitions and methods - leading to adjusted figure of 125,550 people in treatment during 
2003/04 (almost 30,000 fewer than overall estimate based on previous methods). Also, numbers 
exclude people treated in prison (7,500 in 2003/04) or outside of England 
Completed: successfully completed treatment during year, including being referred to other agencies. 
figure is excluded from total annual number (i. e. total based on retained and left treatment cases only) 
Retained: remaining in treatment at end of year 
Left: dropped out of treatment during the year (not reported from 03/04, but inferred from total (in 
italics) 
^ figure for 2003/04 revised in October 2005 (in report on 2004/05 figures) - from 125,900 (i. e. 350 
lower) 
Source: www. nta. nhs. uk 
Clearly the numbers (and percentages) of those retained in treatment is increasing, 
however those successfully completing treatment (or being referred to other agencies) 
has remained static at 10%, and given the ever increasing numbers entering treatment 
this figure alone suggests alternative approaches need to be investigated. 
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5.1 Conclusions 
In conclusion, empirical evidence seems to be the key to addressing the who, why and 
how questions associated with prescribing heroin. The gathering of such evidence 
needs government funding, clinical support and client co-operation, and the successful 
involvement of all three could potentially lead to unique and mutually beneficial 
developments in treatment policy and practice. 
In one of the very few studies which sought the opinions of drug using clients as to 
the merits of injectable heroin (and methadone) prescribing, three key features were 
apparent in terms of client motivation; a desire to obtain a safe drug supply of known 
dose, to improve family relationships, and to avoid getting into trouble with the 
police. (Sell & Zador 2004). 
It is clear that implementing a research/evidence based coherent strategy to prescribe 
heroin, or to at least develop a large scale pilot study to look at the feasibility of a 
genuinely flexible national prescribing policy, needs to be a priority for all involved. 
Any future decisions regarding the treatment of opioid clients need to be made in a 
context of transparent and measurable outcomes, based firmly on the commitment, at 
all levels, to reduce harm. 
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APPENDIX ONE - QUESTIONNAIRE 
126 
Thank you for agreeing to take part in this 
short, confidential study. 
THE PURPOSE OF THIS STUDY IS TO FIND OUT WHAT YOU 
FEELABOUT YOUR CURRENT'SCRIPT, AND HOW IT FFECTS 
YOUR EVERYDAY LIFE. 
ALL OF THE ANSWERS YOU GIVE ARE COMPLETELY 
CONFIDENTIAL NO INFORMATION ABOUT ANY INDIVIDUAL 
CLIENT WILL BE PASSED ON TO THE CLINIC STAFF, 
OR TO ANYONE ELSE. 
AS A PARTICIPANT IN THIS PIECE OF WORK, YOU WILL HAVE 
ACCESS TO ITS FINDINGS AND CONCLUSIONS. 
WHEN YOU HAVE COMPLETED THE QUESTIONNAIRE, 
PLEASE RETURN IT TO ME IN PERSON, OR 
IF YOU PREFER POST IT DIRECTLY TO ME IN 
THE CONFIDENTIAL, FREEPOST ENVELOPE PROVIDED. 
Once again, thank you for your co-operation 
Sally Woods 
Liverpool John Moores University 
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Section A: Questions about your'script. 
1 What is your current script? 
[Please give as much detail as possible e. g. Methadone, diamorphine, 
etc? Amps, mixture, reefers etc? How many mg's / ml's? 
AMPS: (how much? ) 
MIXTURE: (how much? ) 
REEFERS: (how much? ) 
OTHER: (how much? ) 
2 Approximately how long have you been on this 'script? 
YEARS MONTHS or WEEKS 
3 How happy are you with this 'script? 
(please circle one number) 
12345 
very unhappy unhappy neutral happy very happy 
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4 Who decided that you should have the 'script you are now on? 
(please tick one response) 
You 
The clinical staff 
A joint decision between you and the staff 
5 If you could, would you like to change your'script? 
NO [] (please go on to question 6, on the next page) 
YES [] a] How would you like to change your'script? 
b] Why would you like to change your'script? 
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Section B: Questions about drugs you use in addition to your clinic'script 
le, those you use to "top up" the effects of your'script 
THE FOLLOWING QUESTIONS ASK ABOUT YOUR DRUG USE OVER 
THE LAST MONTH: 
6 On average, during the last month, how much and how often did you 
consume any of the following? 
(please say how much and how often for each, and leave the line 
blank if you didn't use that particular drug) 
HOW MUCH 
PER DAY /WEEK 
(e. g. CANNABIS 
a)Cannabis 
b)Nicotine 
%ounce per week 
c)Alcohol 
HOW OFTEN 
DID YOU TAKE IT 
every day 
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7 APART from the `script you receive from the clinic, what other drugs 
have you taken In the last month? 
(for each drug you used, please give an average estimate of how 
much used in a week, and how often you used it, if you did not use 
any drugs, please go to SECTION C) 
DRUG 
(e. g., Heroin 
A) HEROIN 
B) DIAMORPHINE 
C) METHADONE 
D) AMPHETAMINE 
E) COCAINE 
F) OTHERS: please state 
HOW MUCH IN 
THE WEEK / MONTH 
4 grams per week 
HOW OFTEN 
DID YOU TAKE IT 
every day) 
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8 DURING THE LAST MOMTH, have you INJECTED any of the drugs 
you use to "top up" your `script? 
(do not include any injectables which you receive as part /all of your 
'script 
NO [] (please go on to question 9) 
YES [] a) Which drugs? 
b) DURING THE LAST MONTH, how often have you 
injected "top up" drugs? (please tick one box only) 
7 or more times per day [] 
3-6 times per day [] 
1-2 times per day [] 
3-6 times per week [] 
1-2 times per week [] 
1-3 times per month [] 
9 Where do you get these extra "top ups" from? 
(please tick all appropriate boxes, I don't want any names etc) 
Other registered users [] 
(i. e., part of someone else's 'script) 
Other users (not registered) [] 
(i. e., drugs from the street) 
Family member / Partner [] 
Dealer 
GP/ Health Centre Other (please specify) [] 
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10 ON AVERAGE, how much do you pay for the drugs you use to "top up" 
your clinic `script? Please indicate in what form you buy the 
drug/s e. g., Amps, Reefers etc. (please leave the line blank if 
you do not use that particular drug, and add any others you use in 
spaces g and h) 
HOW MUCH DO YOU PAY? 
a) HEROIN: 
b) DIAMORPHINE: 
c) METHADONE: 
d) COCAINE: 
e) AMPETHAMINES: 
f) TRANQILLISERS: 
g) 
h) 
11 Do you use either of the following to finance your "top up" drug use? 
(please tick one box in each row) 
YES NO 
Wages [][l 
Social Security / Benefits [lII 
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SECTION C 
12 DURING THE LAST MONTH, please indicate how often, if at all, you 
engaged in any of the following activities: 
(please tick only one box in each row) 
HOW OFTEN? 
Every 3-4 times 1-2 times once a once a not in the 
day per week per week fortnight month last month 
Burglary [][][][][][] 
hop Lifting 3 
dealing part/all [] 
of your `script 
Dealing [J 
street drugs 
'rostitution [] 
(heft from family [] 
Jther [] 
, please specify 
13 Why do you / did you engage in any of the above activities? 
(please give as much detail as you can) 
LIVE -COL 
JOHN MOORES UNIVERSITY 134 AVAIL ROB-ARTS LIlC 
TEL 0151 2: 31 1027 
14 If you were able to receive the `script you wanted, would this effect your 
criminal behaviour? 
NO [] (please go on to question 15) 
YES [] a) How would your criminal behaviour be effected? 
SECTION D: Questions asking how you feel about your life and about 
your drug use. 
(please circle the number which most closely matches your feelings) 
15 How much of your time do you feel is being taken up by drug use? 
(this includes getting to the clinic, collecting your `script, and the time it 
takes to get hold of any "top up" drugs, e. g., finding the cash, selling 
stolen goods, prostitution, getting to the dealer, taking drugs etc. ) 
1 
Less than 
1 hour/day 
2 
2-4 
hours/day 
3 
5 -7 
hours/day 
4 
8-10 
hours/day 
5 
over 10 
hours/day 
16 How well do you feel you are coping with your new life now? 
(for example do you feel you are generally in control of what's going on 
for you) 
1234 
coping coping coping coping 
very badly badly sometimes well 
5 
coping 
very well 
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17a How does your current quality of life compare to how it was 1 
month ago? 
(for example do you generally feel any better or worse than you 
did then) 
2345 
a lot worse worse no difference better a lot better 
17b If your quality of life has changed - what do you feel has caused 
this? 
18 What do you feel are the main factors that influence your current drug 
use? 
COULD YOU PLEASE END BY GIVING SOME GENERAL 
INFORMATION: 
(This information will be coded and then this section will be detached from 
the questionnaire) 
Are you mate or female? 
What is your date of birth? / 119 
Thanks for your help, its appreciated. 
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APPENDIX TWO - CHI SQUARE RAW DATA 
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Raw data/frequencies for Chi Square Calculations. 
Illicit Drug Use. 
Clients on mixture scripts were significantly more likely to use speed than clients on 
reefers or ampoules. 
use speed? * Script include mixture Crosstabulation 
Script include mixture 
0 1 Total 
use speed? no Count 60 67 127 
% within Script 
include mixture 
100.0% 91.8% 95.5% 
yes Count 6 6 
% within Script 
include mixture 
8.2% ý° 4.5% ý° 
Total Count 60 73 133 
% within Script 
include mixture 
100.0% 100.0% 100.0% 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
2-sided 
Exact Sig. 
1-sided 
Pearson Chi-Square 5.164 1 . 023 
Continuity Correctiona 3.433 1 . 064 
Likelihood Ratio 7.431 1 . 006 
Fisher's Exact Test 
. 
032 
. 
025 
Linear-by-Linear 
Association 5.126 1 . 024 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b" 2 cells (50.0%) have expected count less than 5. The minimum expected count is 
2.71. 
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Clients on ampoules were significantly more likely to use cocaine than clients on 
reefers or mixture. 
use cocaine? * Script includes amps Crosstabulation 
Script includes amps 
0 1 Total 
use cocaine? no Count 90 21 111 
% within Script 
includes amps 
88.2% 67.7% 83.5% 
yes Count 12 10 22 
% within Script 
includes amps 
11.8% 32.3% 16.5% 
Total Count 102 31 133 
% within Script 
includes amps 
100.0% 100.0% 100.0% 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
2-sided 
Exact Sig. 
1-sided 
Pearson Chi-Square 7.233 1 . 
007 
Continuity Correction3 5.824 1 . 016 
Likelihood Ratio 6.435 1 . 011 
Fisher's Exact Test 
. 012 . 010 
Linear-by-Linear 
Association 7.178 1 . 
007 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
5.13. 
Criminal Activities 
Clients on reefers are significantly less likely to shoplift compared with other clients 
(mainly on mixture or ampoules). 
SHOPLIFT * Script includes reefers Crosstabulation 
Script includes reefers 
0 1 Total 
SHOPLIFT . 00 
Count 50 37 87 
% within Script 
includes reefers 
58.8% 77.1% 65.4% 
1.00 Count 35 11 46 
% within Script 
includes reefers 
41.2% 22.9% 34.6% 
Total Count 85 48 133 
% within Script 
includes reefers 
100.0% 100.0% 100.0% 
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Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
2-sided 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 4.521 1 
. 
033 
Continuity Correction' 3.750 1 
. 053 
Likelihood Ratio 4.682 1 
. 
030 
Fisher's Exact Test 
. 
038 . 025 
Linear-by-Linear 
Association 4.487 1 . 034 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
16.60. 
Clients on mixture were significantly more likely to do prostitution than other clients 
(mainly on ampoules or reefers). 
PROSTIT * Script include mixture Crosstabulation 
Script include mixture 
0 1 Total 
- PROSTIT . 00 Count 60 67 127 
% within Script 
include mixture 
o 100.0 /0 0 91.8 /0 0 95.5 /o 
1.00 Count 6 6 
% within Script 
include mixture 
o 8.2 /0 0 4.5 /o 
Total Count 60 73 133 
% within Script 
include mixture 
o 100.0 /0 0 100.0 /a 0 100.0 /o 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 5.164 1 
. 
023 
Continuity Correction3 3.433 1 
. 
064 
Likelihood Ratio 7.431 1 
. 
006 
Fisher's Exact Test 
. 032 . 
025 
Linear-by-Linear 
Association 5.126 1 . 024 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 
2.71. 
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Crime and Drug Use 
Clients who reported buying drugs within the last month were significantly more 
likely to do 1+ additional crime/s in the past month than clients who had not. 
buy illicit drugs (past month) * ACQCRIM Crosstabulation 
ACQCRIM 
no 1+ of 6 crimes Total 
buy illicit drugs no Count 26 14 40 
(past month) % within buy illicit 
drugs (past month) 
65.0% 35.0% 100.0% 
yes Count 22 57 79 
% within buy illicit 
drugs (past month) 
27.8% 72.2% 100.0% 
Total Count 48 71 119 
% within buy illicit 
drugs (past month) 
40.3% 59.7% 100.0% 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
2-sided 
Exact Sig. 
1-sided 
Pearson Chi-Square 15.230 1 
. 
000 
Continuity Correctiona 13.725 1 
. 000 
Likelihood Ratio 15.241 1 
. 000 
Fisher's Exact Test 
. 
000 
. 000 
Linear-by-Linear 
Association 15.102 1 . 000 
N of Valid Cases 119 
a" Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
16.13. 
Clients who reported using illicit drugs within the last month were significantly more 
likely to do 1+ additional crime/s in the past month than clients who had not. 
used illicit drug in past month * ACQCRIM Crosstabulation 
ACQCRIM 
no 1+ of 6 crimes Total 
used illicit drug no Count 27 13 40 
in past month % within used illicit 
drug in past month 
67.5% 32.5% 100.0% 
yes Count 22 71 93 
% within used illicit 
drug in past month 
23.7% 76.3% 100.0% 
Total Count 49 84 133 
% within used illicit 
drug in past month 
36.8% 63.2% 100.0% 
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Chi-Square Tests 
Value df 
Asymp. Sig. 
2-sided 
Exact Sig. 
2-sided 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 23.107 1 
. 
000 
Continuity CorrectiorP 21.261 1 
. 
000 
Likelihood Ratio 22.854 1 
. 
000 
Fisher's Exact Test 
. 000 . 
000 
Linear-by-Linear 
Association 22.933 1 . 
000 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
14.74. 
7lients who reported using illicit heroin within the last month were significantly more 
ikely to do 1+ additional crime/s in the past month than clients who had not. 
use illicit heroin? * ACQCRIM Crosstabulation 
ACQCRIM 
no 1+ of 6 crimes Total 
use illicit no Count 
heroin? % within use illicit heroin? 
29 
55.8% 
23 
44.2% 
52 
100.0% 
yes Count 
% within use illicit heroin? 
20 
24.7% 
61 
75.3% 
81 
100.0% 
Total Count 
% within use illicit heroin? 
49 
36.8% 
84 
63.2% 
133 
100.0% 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
2-sided 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 13.145 1 . 
000 
Continuity Corrections 11.844 1 
. 
001 
Likelihood Ratio 13.119 1 
. 
000 
Fisher's Exact Test 
. 
000 . 
000 
Linear-by-Linear 
Association 13.046 1 . 
000 
N of Valid Cases 133 
a" Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
19.16. 
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C 
Clients who reported using illicit cocaine within the last month were significantly 
more likely to do 1+ additional crime/s in the past month than clients who had not. 
use cocaine? * ACQCRIM Crosstabulation 
ACQCRIM 
no 1+ of 6 crimes Total 
use cocaine? no Count 
% within use cocaine? 
49 
44.1% 
62 
55.9% 
111 
100.0% 
yes Count 
% within use cocaine? 
22 
100.0% 
22 
100.0% 
Total Count 
% within use cocaine? 
49 
36.8% 
84 
63.2% 
133 
100.0% 
Chi-Square Tests 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Pearson Chi-Square 15.377 1 
. 
000 
Continuity Corrections 13.538 1 
. 
000 
Likelihood Ratio 22.705 1 
. 
000 
Fisher's Exact Test 
. 000 . 000 
Linear-by-Linear 
Association 15.261 1 . 000 
N of Valid Cases 133 
a. Computed only for a 2x2 table 
b. 0 cells (. 0%) have expected count less than 5. The minimum expected count is 
8.11. 
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